https://trial.medpath.com/news/camrelizumab-plus-chemotherapy-shows-promise-in-cervical-cancer-treatment-with-100-disease-control-rate 2025-02-25T14:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camrelizumab-plus-chemotherapy-shows-promise-in-cervical-cancer-treatment-with-100-disease-control-rate 2025-02-25T14:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-restructures-operations-to-extend-cash-runway-prioritizes-rvu120-blood-cancer-program 2025-02-25T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-restructures-operations-to-extend-cash-runway-prioritizes-rvu120-blood-cancer-program 2025-02-25T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/cognition-therapeutics-reveals-promising-biomarker-strategy-for-alzheimer-s-treatment-patient-selection 2025-02-25T13:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognition-therapeutics-reveals-promising-biomarker-strategy-for-alzheimer-s-treatment-patient-selection 2025-02-25T13:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/venus-remedies-and-infex-therapeutics-partner-to-develop-novel-antibiotic-resistance-fighter-met-x 2025-02-25T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venus-remedies-and-infex-therapeutics-partner-to-develop-novel-antibiotic-resistance-fighter-met-x 2025-02-25T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-expands-zepbound-weight-loss-drug-access-with-new-doses-and-lower-cash-prices 2025-02-25T13:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-expands-zepbound-weight-loss-drug-access-with-new-doses-and-lower-cash-prices 2025-02-25T13:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/lag-3-immunotherapies-market-poised-for-explosive-growth-with-next-generation-therapies-advancing-across-major-markets 2025-02-25T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lag-3-immunotherapies-market-poised-for-explosive-growth-with-next-generation-therapies-advancing-across-major-markets 2025-02-25T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/miltenyi-biotec-launches-india-s-first-cell-gene-therapy-center-of-excellence-in-hyderabad 2025-02-25T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miltenyi-biotec-launches-india-s-first-cell-gene-therapy-center-of-excellence-in-hyderabad 2025-02-25T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/sterotherapeutics-launches-phase-2-trial-of-novel-cushing-s-syndrome-treatment-st-002 2025-02-25T11:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sterotherapeutics-launches-phase-2-trial-of-novel-cushing-s-syndrome-treatment-st-002 2025-02-25T11:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-protocol-for-cambium-bio-s-phase-3-trial-of-elate-ocular-in-dry-eye-disease 2025-02-25T10:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-protocol-for-cambium-bio-s-phase-3-trial-of-elate-ocular-in-dry-eye-disease 2025-02-25T10:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/mankind-pharma-advances-novel-oral-anti-obesity-drug-in-phase-2-trials 2025-02-25T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mankind-pharma-advances-novel-oral-anti-obesity-drug-in-phase-2-trials 2025-02-25T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-16-of-phase-2-cancer-trial-patients-receive-eventually-fda-approved-drugs 2025-02-25T10:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-16-of-phase-2-cancer-trial-patients-receive-eventually-fda-approved-drugs 2025-02-25T10:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/verana-health-and-nanoscope-partner-to-leverage-70000-patient-database-for-retinitis-pigmentosa-gene-therapy-research 2025-02-25T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verana-health-and-nanoscope-partner-to-leverage-70000-patient-database-for-retinitis-pigmentosa-gene-therapy-research 2025-02-25T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-technology-shows-promise-in-rx-to-otc-drug-transition-study-reports-petros-pharmaceuticals 2025-02-25T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-technology-shows-promise-in-rx-to-otc-drug-transition-study-reports-petros-pharmaceuticals 2025-02-25T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-treated-with-eshunt-system-in-landmark-nph-trial-marking-new-era-in-hydrocephalus-treatment 2025-02-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-treated-with-eshunt-system-in-landmark-nph-trial-marking-new-era-in-hydrocephalus-treatment 2025-02-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/monument-therapeutics-raises-ps850k-to-advance-novel-schizophrenia-cognitive-treatment-mt1988 2025-02-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monument-therapeutics-raises-ps850k-to-advance-novel-schizophrenia-cognitive-treatment-mt1988 2025-02-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridgene-and-takeda-form-770m-alliance-to-tackle-undruggable-targets-in-neurology-and-immunology 2025-02-25T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgene-and-takeda-form-770m-alliance-to-tackle-undruggable-targets-in-neurology-and-immunology 2025-02-25T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/grade-guidelines-reinforce-intranasal-corticosteroids-as-first-line-therapy-for-chronic-rhinosinusitis-with-nasal-polyps 2025-02-25T08:00:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grade-guidelines-reinforce-intranasal-corticosteroids-as-first-line-therapy-for-chronic-rhinosinusitis-with-nasal-polyps 2025-02-25T08:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-critical-gap-less-than-1-of-us-clinical-trials-include-pregnant-participants 2025-02-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-critical-gap-less-than-1-of-us-clinical-trials-include-pregnant-participants 2025-02-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/swog-s1815-nab-paclitaxel-addition-to-standard-chemotherapy-under-investigation-for-advanced-biliary-tract-cancer 2025-02-25T07:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swog-s1815-nab-paclitaxel-addition-to-standard-chemotherapy-under-investigation-for-advanced-biliary-tract-cancer 2025-02-25T07:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/ema-expands-lanadelumab-approval-with-new-subcutaneous-dosing-options-for-hae-patients 2025-02-25T07:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-expands-lanadelumab-approval-with-new-subcutaneous-dosing-options-for-hae-patients 2025-02-25T07:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-refuse-to-file-letter-for-wakix-in-idiopathic-hypersomnia-treatment 2025-02-25T07:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-refuse-to-file-letter-for-wakix-in-idiopathic-hypersomnia-treatment 2025-02-25T07:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/korean-hospitals-secure-approval-for-sk-biopharmaceuticals-cenobamate-for-epilepsy-treatment 2025-02-25T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-hospitals-secure-approval-for-sk-biopharmaceuticals-cenobamate-for-epilepsy-treatment 2025-02-25T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-averto-medical-s-coloseal-system-for-ostomy-free-colorectal-surgery 2025-02-25T06:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-averto-medical-s-coloseal-system-for-ostomy-free-colorectal-surgery 2025-02-25T06:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/veloxis-pharmaceuticals-transplant-candidate-vel-101-receives-official-name-pegrizeprument 2025-02-25T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veloxis-pharmaceuticals-transplant-candidate-vel-101-receives-official-name-pegrizeprument 2025-02-25T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-brain-directed-gene-therapy-upstaza-receives-eu-recommendation-for-rare-aadc-deficiency 2025-02-25T05:01:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-brain-directed-gene-therapy-upstaza-receives-eu-recommendation-for-rare-aadc-deficiency 2025-02-25T05:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/limited-uptake-of-core-outcome-set-in-coronary-artery-disease-trials-despite-2015-standardization-effort 2025-02-25T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/limited-uptake-of-core-outcome-set-in-coronary-artery-disease-trials-despite-2015-standardization-effort 2025-02-25T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/scripps-research-develops-long-acting-injectable-version-of-anti-malaria-drug-atovaquone 2025-02-25T04:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scripps-research-develops-long-acting-injectable-version-of-anti-malaria-drug-atovaquone 2025-02-25T04:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-rallies-behind-diversity-in-clinical-trials-despite-regulatory-uncertainty 2025-02-25T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-rallies-behind-diversity-in-clinical-trials-despite-regulatory-uncertainty 2025-02-25T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-unveils-ambitious-pipeline-and-platform-innovation-at-r-d-day 2025-02-25T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-unveils-ambitious-pipeline-and-platform-innovation-at-r-d-day 2025-02-25T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dcgi-mandates-safety-data-submission-for-two-legacy-combination-drugs-within-3-months 2025-02-25T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dcgi-mandates-safety-data-submission-for-two-legacy-combination-drugs-within-3-months 2025-02-25T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-triple-immunotherapy-combination-shows-promise-in-pd-1-resistant-gastroesophageal-cancer 2025-02-25T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-triple-immunotherapy-combination-shows-promise-in-pd-1-resistant-gastroesophageal-cancer 2025-02-25T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/chilean-rsv-vaccine-advances-to-phase-2-clinical-trials-in-europe-targeting-elderly-population 2025-02-25T01:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chilean-rsv-vaccine-advances-to-phase-2-clinical-trials-in-europe-targeting-elderly-population 2025-02-25T01:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/evolutionaryscale-launches-with-142m-to-transform-drug-discovery-using-advanced-ai-protein-platform 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolutionaryscale-launches-with-142m-to-transform-drug-discovery-using-advanced-ai-protein-platform 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-adds-90-innovative-drugs-to-national-reimbursement-list-boosting-access-to-cancer-and-rare-disease-treatments 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-adds-90-innovative-drugs-to-national-reimbursement-list-boosting-access-to-cancer-and-rare-disease-treatments 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/carb-x-awards-2-million-to-immunethep-for-novel-e-coli-vaccine-development 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carb-x-awards-2-million-to-immunethep-for-novel-e-coli-vaccine-development 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mrna-delivery-system-bypasses-liver-for-targeted-ibd-treatment 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mrna-delivery-system-bypasses-liver-for-targeted-ibd-treatment 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-partners-with-zhuhai-sb-xinchuang-to-advance-allogeneic-car-t-development-in-china 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-partners-with-zhuhai-sb-xinchuang-to-advance-allogeneic-car-t-development-in-china 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/orasis-pharmaceuticals-prepares-for-march-launch-of-fda-approved-presbyopia-eye-drop-qlosi 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orasis-pharmaceuticals-prepares-for-march-launch-of-fda-approved-presbyopia-eye-drop-qlosi 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-secures-patent-for-novel-evm401-compounds-targeting-mental-health-treatment 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-secures-patent-for-novel-evm401-compounds-targeting-mental-health-treatment 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/epicore-biosystems-secures-32m-in-expanded-series-b-for-advanced-sweat-sensing-wearable-technology 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epicore-biosystems-secures-32m-in-expanded-series-b-for-advanced-sweat-sensing-wearable-technology 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-poziotinib-for-her2-mutated-nsclc-following-advisory-committee-s-negative-vote 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-poziotinib-for-her2-mutated-nsclc-following-advisory-committee-s-negative-vote 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharmaceuticals-reaches-7m-settlement-in-us-antitrust-lawsuits-over-cholesterol-drugs 2025-02-24T22:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-pharmaceuticals-reaches-7m-settlement-in-us-antitrust-lawsuits-over-cholesterol-drugs 2025-02-24T22:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-denies-invivyd-s-eua-expansion-request-for-covid-19-antibody-pemgarda 2025-02-24T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-denies-invivyd-s-eua-expansion-request-for-covid-19-antibody-pemgarda 2025-02-24T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/hemogenyx-initiates-first-human-dosing-of-car-t-therapy-for-resistant-acute-myeloid-leukemia 2025-02-24T22:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemogenyx-initiates-first-human-dosing-of-car-t-therapy-for-resistant-acute-myeloid-leukemia 2025-02-24T22:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-ozempic-s-potential-as-depression-treatment-in-landmark-analysis 2025-02-24T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-ozempic-s-potential-as-depression-treatment-in-landmark-analysis 2025-02-24T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-enhertu-r-approval-for-her2-low-ultralow-metastatic-breast-cancer-in-eu 2025-02-24T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-recommends-enhertu-r-approval-for-her2-low-ultralow-metastatic-breast-cancer-in-eu 2025-02-24T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-roche-s-lunsumio-for-follicular-lymphoma-treatment 2025-02-24T19:33:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-roche-s-lunsumio-for-follicular-lymphoma-treatment 2025-02-24T19:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/darolutamide-falls-short-in-phase-ii-trial-for-ar-positive-triple-negative-breast-cancer 2025-02-24T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/darolutamide-falls-short-in-phase-ii-trial-for-ar-positive-triple-negative-breast-cancer 2025-02-24T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-plasma-exchange-shows-no-benefit-for-long-covid-treatment-in-phase-ii-trial 2025-02-24T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-plasma-exchange-shows-no-benefit-for-long-covid-treatment-in-phase-ii-trial 2025-02-24T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/anti-pd1-precision-therapy-shows-promise-in-unresectable-stage-iii-nsclc-trial 2025-02-24T19:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-pd1-precision-therapy-shows-promise-in-unresectable-stage-iii-nsclc-trial 2025-02-24T19:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/hsd3b1-gene-variant-linked-to-poorer-survival-in-prostate-cancer-despite-intensive-therapy 2025-02-24T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hsd3b1-gene-variant-linked-to-poorer-survival-in-prostate-cancer-despite-intensive-therapy 2025-02-24T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/physical-activity-significantly-improves-survival-outcomes-in-stage-iii-colon-cancer-patients 2025-02-24T19:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physical-activity-significantly-improves-survival-outcomes-in-stage-iii-colon-cancer-patients 2025-02-24T19:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/ema-to-review-novel-topical-gene-therapy-beremagene-geperpavec-among-six-new-drug-applications 2025-02-24T19:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-to-review-novel-topical-gene-therapy-beremagene-geperpavec-among-six-new-drug-applications 2025-02-24T19:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-reports-favorable-safety-profile-for-novel-pknp-cancer-treatment-technology 2025-02-24T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-reports-favorable-safety-profile-for-novel-pknp-cancer-treatment-technology 2025-02-24T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-reports-strong-growth-and-strategic-acquisition-of-ambry-genetics-in-q4-2024 2025-02-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-reports-strong-growth-and-strategic-acquisition-of-ambry-genetics-in-q4-2024 2025-02-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-files-lawsuit-against-samsung-bioepis-over-stelara-biosimilar-contract-dispute 2025-02-24T17:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-files-lawsuit-against-samsung-bioepis-over-stelara-biosimilar-contract-dispute 2025-02-24T17:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-ltz-301-a-novel-myeloid-engager-therapy-for-b-cell-lymphoma 2025-02-24T17:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-ltz-301-a-novel-myeloid-engager-therapy-for-b-cell-lymphoma 2025-02-24T17:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-novel-riptac-cancer-therapy-trial-for-advanced-prostate-cancer 2025-02-24T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-novel-riptac-cancer-therapy-trial-for-advanced-prostate-cancer 2025-02-24T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-partners-with-pfizer-to-evaluate-novel-cancer-drug-combination-amid-financial-losses 2025-02-24T17:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-partners-with-pfizer-to-evaluate-novel-cancer-drug-combination-amid-financial-losses 2025-02-24T17:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/versamune-r-hpv-shows-promising-ctdna-clearance-and-survival-rates-in-advanced-cervical-cancer-trial 2025-02-24T16:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/versamune-r-hpv-shows-promising-ctdna-clearance-and-survival-rates-in-advanced-cervical-cancer-trial 2025-02-24T16:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/azitra-advances-clinical-programs-for-netherton-syndrome-and-egfr-inhibitor-associated-rash 2025-02-24T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azitra-advances-clinical-programs-for-netherton-syndrome-and-egfr-inhibitor-associated-rash 2025-02-24T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/pepgen-reports-promising-splicing-correction-results-in-dm1-clinical-trial 2025-02-24T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepgen-reports-promising-splicing-correction-results-in-dm1-clinical-trial 2025-02-24T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-cbp-101-for-recurrent-endometrial-cancer-treatment 2025-02-24T16:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-cbp-101-for-recurrent-endometrial-cancer-treatment 2025-02-24T16:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-exclusivity-to-lumryz-for-narcolepsy-treatment-marking-first-once-nightly-oxybate-therapy 2025-02-24T16:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-exclusivity-to-lumryz-for-narcolepsy-treatment-marking-first-once-nightly-oxybate-therapy 2025-02-24T16:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/ataciguat-shows-promise-in-slowing-aortic-valve-stenosis-progression-mayo-clinic-study-reveals 2025-02-24T16:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ataciguat-shows-promise-in-slowing-aortic-valve-stenosis-progression-mayo-clinic-study-reveals 2025-02-24T16:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/sonia-trial-reveals-optimal-timing-for-cdk4-6-inhibitors-in-advanced-breast-cancer-treatment 2025-02-24T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonia-trial-reveals-optimal-timing-for-cdk4-6-inhibitors-in-advanced-breast-cancer-treatment 2025-02-24T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/co-diagnostics-withdraws-covid-19-test-fda-application-plans-enhanced-version-submission 2025-02-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/co-diagnostics-withdraws-covid-19-test-fda-application-plans-enhanced-version-submission 2025-02-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-pdufa-date-for-glaukos-ilink-epi-on-for-non-surgical-keratoconus-treatment 2025-02-24T15:01:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-pdufa-date-for-glaukos-ilink-epi-on-for-non-surgical-keratoconus-treatment 2025-02-24T15:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-cancer-vaccines-show-promise-in-clinical-trials-marking-new-era-in-immunotherapy 2025-02-24T14:52:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-cancer-vaccines-show-promise-in-clinical-trials-marking-new-era-in-immunotherapy 2025-02-24T14:52:19+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-s-gene-therapy-shows-promising-visual-benefits-in-children-with-rare-genetic-blindness 2025-02-24T14:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-s-gene-therapy-shows-promising-visual-benefits-in-children-with-rare-genetic-blindness 2025-02-24T14:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-tau-secures-mdsap-certification-for-alpha-dart-cancer-therapy-manufacturing-facility 2025-02-24T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-tau-secures-mdsap-certification-for-alpha-dart-cancer-therapy-manufacturing-facility 2025-02-24T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/rxc008-shows-promise-as-first-in-class-treatment-for-fibrostenotic-crohn-s-disease-in-phase-1-trial 2025-02-24T13:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rxc008-shows-promise-as-first-in-class-treatment-for-fibrostenotic-crohn-s-disease-in-phase-1-trial 2025-02-24T13:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-shifts-phase-3-mac-lung-disease-trial-to-quality-of-life-endpoint 2025-02-24T13:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-shifts-phase-3-mac-lung-disease-trial-to-quality-of-life-endpoint 2025-02-24T13:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-novel-cell-therapy-for-dry-amd-treatment 2025-02-24T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-novel-cell-therapy-for-dry-amd-treatment 2025-02-24T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/healx-initiates-phase-2-trial-of-ai-discovered-hlx-1502-for-neurofibromatosis-type-1-treatment 2025-02-24T13:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healx-initiates-phase-2-trial-of-ai-discovered-hlx-1502-for-neurofibromatosis-type-1-treatment 2025-02-24T13:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/summit-and-pfizer-partner-to-evaluate-novel-cancer-therapy-combinations-with-ivonescimab 2025-02-24T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-and-pfizer-partner-to-evaluate-novel-cancer-therapy-combinations-with-ivonescimab 2025-02-24T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-and-trialnet-partner-to-test-novel-t-cell-therapy-rezpegaldesleukin-in-early-stage-type-1-diabetes 2025-02-24T13:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-and-trialnet-partner-to-test-novel-t-cell-therapy-rezpegaldesleukin-in-early-stage-type-1-diabetes 2025-02-24T13:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/gylden-pharma-advances-t-cell-priming-platform-with-multiple-clinical-trials-for-infectious-diseases-in-2025 2025-02-24T13:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gylden-pharma-advances-t-cell-priming-platform-with-multiple-clinical-trials-for-infectious-diseases-in-2025 2025-02-24T13:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-177-psma-617-shows-promise-in-advanced-prostate-cancer-treatment 2025-02-24T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutetium-177-psma-617-shows-promise-in-advanced-prostate-cancer-treatment 2025-02-24T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/xeris-biopharma-appoints-dr-anh-nguyen-as-chief-medical-officer-to-lead-product-development-strategy 2025-02-24T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xeris-biopharma-appoints-dr-anh-nguyen-as-chief-medical-officer-to-lead-product-development-strategy 2025-02-24T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/familiescn2a-and-cellectricon-join-forces-to-advance-drug-development-for-autism-and-epilepsy-linked-scn2a-gene 2025-02-24T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/familiescn2a-and-cellectricon-join-forces-to-advance-drug-development-for-autism-and-epilepsy-linked-scn2a-gene 2025-02-24T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-launches-comprehensive-bimzelx-navigate-program-to-enhance-patient-access-and-support 2025-02-24T11:54:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-launches-comprehensive-bimzelx-navigate-program-to-enhance-patient-access-and-support 2025-02-24T11:54:43+00:00 hourly 0.9 https://trial.medpath.com/news/berkshire-biomedical-launches-equity-crowdfunding-for-revolutionary-copatm-medication-delivery-system 2025-02-24T11:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/berkshire-biomedical-launches-equity-crowdfunding-for-revolutionary-copatm-medication-delivery-system 2025-02-24T11:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-new-pre-filled-pen-option-for-takhzyro-in-hereditary-angioedema-treatment 2025-02-24T10:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-new-pre-filled-pen-option-for-takhzyro-in-hereditary-angioedema-treatment 2025-02-24T10:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/ngm-bio-initiates-phase-2-trial-of-ngm120-for-hyperemesis-gravidarum-treatment 2025-02-24T10:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ngm-bio-initiates-phase-2-trial-of-ngm120-for-hyperemesis-gravidarum-treatment 2025-02-24T10:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-enrolled-in-phase-ib-ii-trial-of-tasquinimod-for-treatment-resistant-myelofibrosis 2025-02-24T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-enrolled-in-phase-ib-ii-trial-of-tasquinimod-for-treatment-resistant-myelofibrosis 2025-02-24T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-drug-evaluation-director-patrizia-cavazzoni-appointed-as-pfizer-s-chief-medical-officer 2025-02-24T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-fda-drug-evaluation-director-patrizia-cavazzoni-appointed-as-pfizer-s-chief-medical-officer 2025-02-24T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funding-cuts-threaten-cancer-research-progress-and-early-career-scientists 2025-02-24T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funding-cuts-threaten-cancer-research-progress-and-early-career-scientists 2025-02-24T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-rockets-nasal-covid-19-vaccine-selected-for-niaid-project-nextgen-advances-cancer-therapeutics-pipeline 2025-02-24T07:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-rockets-nasal-covid-19-vaccine-selected-for-niaid-project-nextgen-advances-cancer-therapeutics-pipeline 2025-02-24T07:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/pioneering-spinal-stimulation-therapy-enables-paralyzed-patient-to-walk-again-in-uk-trial 2025-02-24T07:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pioneering-spinal-stimulation-therapy-enables-paralyzed-patient-to-walk-again-in-uk-trial 2025-02-24T07:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-expands-groundbreaking-car-t-cell-therapy-trial-for-blood-cancer-patients 2025-02-24T07:32:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-expands-groundbreaking-car-t-cell-therapy-trial-for-blood-cancer-patients 2025-02-24T07:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/rna-editing-breakthroughs-show-clinical-promise-with-wave-life-sciences-leading-first-human-results 2025-02-24T07:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rna-editing-breakthroughs-show-clinical-promise-with-wave-life-sciences-leading-first-human-results 2025-02-24T07:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-emergency-authorization-for-20-minute-at-home-molecular-covid-flu-test 2025-02-24T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-emergency-authorization-for-20-minute-at-home-molecular-covid-flu-test 2025-02-24T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/braf-inhibitors-show-promise-in-treatment-of-relapsed-refractory-hairy-cell-leukemia 2025-02-24T06:52:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/braf-inhibitors-show-promise-in-treatment-of-relapsed-refractory-hairy-cell-leukemia 2025-02-24T06:52:10+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-launches-pyzchiva-a-new-ustekinumab-biosimilar-expanding-access-to-critical-autoimmune-treatment-in-us 2025-02-24T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-launches-pyzchiva-a-new-ustekinumab-biosimilar-expanding-access-to-critical-autoimmune-treatment-in-us 2025-02-24T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-launches-innovative-pa-oncology-fellowship-to-address-growing-cancer-care-demands 2025-02-24T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-launches-innovative-pa-oncology-fellowship-to-address-growing-cancer-care-demands 2025-02-24T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tandem-stem-cell-transplant-study-reveals-critical-complications-in-high-risk-neuroblastoma-treatment 2025-02-24T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tandem-stem-cell-transplant-study-reveals-critical-complications-in-high-risk-neuroblastoma-treatment 2025-02-24T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-to-present-new-data-on-bot-bal-combination-therapy-at-aacr-io-meeting 2025-02-24T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-to-present-new-data-on-bot-bal-combination-therapy-at-aacr-io-meeting 2025-02-24T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/biocryst-s-orladeyo-demonstrates-safety-and-efficacy-in-pediatric-hereditary-angioedema-trial 2025-02-24T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocryst-s-orladeyo-demonstrates-safety-and-efficacy-in-pediatric-hereditary-angioedema-trial 2025-02-24T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunovant-s-batoclimab-shows-promise-in-phase-3-myasthenia-gravis-trial-analysts-maintain-strong-buy-rating 2025-02-24T04:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunovant-s-batoclimab-shows-promise-in-phase-3-myasthenia-gravis-trial-analysts-maintain-strong-buy-rating 2025-02-24T04:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/memphasys-achieves-critical-milestone-in-felixtm-system-clinical-trial-for-advanced-sperm-selection 2025-02-24T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memphasys-achieves-critical-milestone-in-felixtm-system-clinical-trial-for-advanced-sperm-selection 2025-02-24T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-expands-precision-oncology-portfolio-with-advanced-liquid-biopsy-and-mrd-testing-solutions 2025-02-24T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-expands-precision-oncology-portfolio-with-advanced-liquid-biopsy-and-mrd-testing-solutions 2025-02-24T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-reveals-similar-outcomes-for-acs-patients-with-and-without-traditional-risk-factors 2025-02-24T04:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-reveals-similar-outcomes-for-acs-patients-with-and-without-traditional-risk-factors 2025-02-24T04:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-introduces-novel-trivalent-vaccine-combining-h5-avian-flu-protection-with-core-poultry-immunizations 2025-02-24T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-introduces-novel-trivalent-vaccine-combining-h5-avian-flu-protection-with-core-poultry-immunizations 2025-02-24T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-licensed-antibiotic-platform-launches-as-kinvard-bio-to-combat-drug-resistant-infections 2025-02-24T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-licensed-antibiotic-platform-launches-as-kinvard-bio-to-combat-drug-resistant-infections 2025-02-24T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/better-choice-company-advances-acquisition-of-srx-health-solutions-following-unanimous-shareholder-approval 2025-02-24T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/better-choice-company-advances-acquisition-of-srx-health-solutions-following-unanimous-shareholder-approval 2025-02-24T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-diabetes-drugs-show-promising-potential-for-mental-health-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-diabetes-drugs-show-promising-potential-for-mental-health-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-launches-novel-insurance-coverage-to-support-leqembi-access-in-japan 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-launches-novel-insurance-coverage-to-support-leqembi-access-in-japan 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-abbv-706-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-abbv-706-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-jagsonpal-pharmaceuticals-for-critical-api-manufacturing-violations 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letter-to-jagsonpal-pharmaceuticals-for-critical-api-manufacturing-violations 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/celularity-and-bluesphere-bio-partner-on-manufacturing-tcr-t-cell-therapies-for-leukemia-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celularity-and-bluesphere-bio-partner-on-manufacturing-tcr-t-cell-therapies-for-leukemia-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-biotech-secures-eur72m-series-a-to-advance-novel-gene-therapy-for-geographic-atrophy 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-biotech-secures-eur72m-series-a-to-advance-novel-gene-therapy-for-geographic-atrophy 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/labconnect-and-australian-clinical-labs-form-strategic-alliance-to-expand-clinical-trial-services-in-asia-pacific 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labconnect-and-australian-clinical-labs-form-strategic-alliance-to-expand-clinical-trial-services-in-asia-pacific 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mgi-tech-and-oncoclinicas-co-partner-to-advance-genomic-cancer-diagnostics-in-brazil 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mgi-tech-and-oncoclinicas-co-partner-to-advance-genomic-cancer-diagnostics-in-brazil 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-pharmaceutical-reshoring-building-resilient-supply-chains-amid-global-disruptions 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-pharmaceutical-reshoring-building-resilient-supply-chains-amid-global-disruptions 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-t-cell-therapy-shows-promising-results-in-castration-resistant-prostate-cancer-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-t-cell-therapy-shows-promising-results-in-castration-resistant-prostate-cancer-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-pharmaceuticals-develops-novel-silver-ii-antimicrobial-to-combat-drug-resistant-infections 2025-02-23T23:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-pharmaceuticals-develops-novel-silver-ii-antimicrobial-to-combat-drug-resistant-infections 2025-02-23T23:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/final-ariel4-trial-results-show-limited-benefit-of-rucaparib-in-brca-ovarian-cancer 2025-02-23T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/final-ariel4-trial-results-show-limited-benefit-of-rucaparib-in-brca-ovarian-cancer 2025-02-23T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/uh-cancer-center-and-queen-s-health-systems-unite-to-launch-hawaii-s-first-on-campus-cancer-clinic 2025-02-23T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uh-cancer-center-and-queen-s-health-systems-unite-to-launch-hawaii-s-first-on-campus-cancer-clinic 2025-02-23T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-validates-fedratinib-s-safety-as-post-transplant-maintenance-therapy-for-mpn-patients 2025-02-23T20:31:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-validates-fedratinib-s-safety-as-post-transplant-maintenance-therapy-for-mpn-patients 2025-02-23T20:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-pioneers-first-human-stroke-treatment-with-stryker-s-novel-broadway-catheter-system 2025-02-23T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wvu-pioneers-first-human-stroke-treatment-with-stryker-s-novel-broadway-catheter-system 2025-02-23T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-landmark-clinical-trial-to-assess-kratom-s-addiction-potential 2025-02-23T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-landmark-clinical-trial-to-assess-kratom-s-addiction-potential 2025-02-23T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/expanding-biologic-options-transform-treatment-landscape-for-psoriatic-arthritis 2025-02-23T12:00:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expanding-biologic-options-transform-treatment-landscape-for-psoriatic-arthritis 2025-02-23T12:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/dm199-s-novel-mechanism-for-acute-stroke-treatment-detailed-in-stroke-journal-publication 2025-02-23T08:01:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dm199-s-novel-mechanism-for-acute-stroke-treatment-detailed-in-stroke-journal-publication 2025-02-23T08:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/shift-in-mash-diagnosis-study-shows-growing-preference-for-noninvasive-testing-over-liver-biopsy 2025-02-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shift-in-mash-diagnosis-study-shows-growing-preference-for-noninvasive-testing-over-liver-biopsy 2025-02-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-fenfluramine-for-children-with-lennox-gastaut-syndrome-offering-new-hope-for-severe-epilepsy-treatment 2025-02-23T01:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-approves-fenfluramine-for-children-with-lennox-gastaut-syndrome-offering-new-hope-for-severe-epilepsy-treatment 2025-02-23T01:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-mysugr-pro-app-demonstrates-significant-reduction-in-diabetes-distress-in-clinical-trial 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-mysugr-pro-app-demonstrates-significant-reduction-in-diabetes-distress-in-clinical-trial 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-laboratories-to-acquire-dutch-injectable-specialist-octoplus-for-eur27-39m 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-laboratories-to-acquire-dutch-injectable-specialist-octoplus-for-eur27-39m 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-reports-promising-results-from-phase-1-2-gene-therapy-trial-plans-phase-3-study 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluebird-bio-reports-promising-results-from-phase-1-2-gene-therapy-trial-plans-phase-3-study 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-s-traumakine-for-ards-receives-uk-s-promising-innovative-medicines-status 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-s-traumakine-for-ards-receives-uk-s-promising-innovative-medicines-status 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/histotripsy-shows-promise-for-treating-multiple-solid-tumors-beyond-liver-cancer 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histotripsy-shows-promise-for-treating-multiple-solid-tumors-beyond-liver-cancer 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/obseva-seeks-fda-approval-for-novel-uterine-fibroid-treatment-with-flexible-hormone-therapy-options 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obseva-seeks-fda-approval-for-novel-uterine-fibroid-treatment-with-flexible-hormone-therapy-options 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-crown-trial-data-establishes-lorlatinib-as-first-line-standard-for-alk-nsclc 2025-02-22T22:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-crown-trial-data-establishes-lorlatinib-as-first-line-standard-for-alk-nsclc 2025-02-22T22:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/novel-causal-forest-analysis-reveals-serum-potassium-s-role-in-vasopressin-treatment-response-for-septic-shock 2025-02-22T22:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-causal-forest-analysis-reveals-serum-potassium-s-role-in-vasopressin-treatment-response-for-septic-shock 2025-02-22T22:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/dual-blood-pressure-medication-strategy-halves-arterial-events-in-veds-patients 2025-02-22T19:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-blood-pressure-medication-strategy-halves-arterial-events-in-veds-patients 2025-02-22T19:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/tezepelumab-shows-remarkable-92-reduction-in-nasal-polyp-surgery-need-in-phase-3-trial 2025-02-22T19:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tezepelumab-shows-remarkable-92-reduction-in-nasal-polyp-surgery-need-in-phase-3-trial 2025-02-22T19:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/shattuck-labs-sl-325-demonstrates-strong-safety-profile-in-pre-clinical-ibd-study 2025-02-22T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shattuck-labs-sl-325-demonstrates-strong-safety-profile-in-pre-clinical-ibd-study 2025-02-22T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-to-showcase-advanced-radiology-portfolio-and-novel-contrast-agent-at-ecr-2025 2025-02-22T16:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-to-showcase-advanced-radiology-portfolio-and-novel-contrast-agent-at-ecr-2025 2025-02-22T16:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/ixinity-demonstrates-strong-safety-and-efficacy-profile-in-young-hemophilia-b-patients 2025-02-22T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ixinity-demonstrates-strong-safety-and-efficacy-profile-in-young-hemophilia-b-patients 2025-02-22T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/omalizumab-shows-strong-real-world-success-one-year-after-food-allergy-approval 2025-02-22T10:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omalizumab-shows-strong-real-world-success-one-year-after-food-allergy-approval 2025-02-22T10:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-oral-a4b7-integrin-inhibitor-nsho-101-shows-promise-for-ibd-treatment-in-phase-1-data 2025-02-22T10:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-oral-a4b7-integrin-inhibitor-nsho-101-shows-promise-for-ibd-treatment-in-phase-1-data 2025-02-22T10:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-and-theramex-partner-to-develop-novel-biodegradable-contraceptive-implant 2025-02-22T10:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dare-bioscience-and-theramex-partner-to-develop-novel-biodegradable-contraceptive-implant 2025-02-22T10:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-policy-change-expands-pharmacists-role-in-medication-abortion-access-bringing-new-challenges 2025-02-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-policy-change-expands-pharmacists-role-in-medication-abortion-access-bringing-new-challenges 2025-02-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/persanta-advances-towards-ipo-with-dominari-securities-to-commercialize-early-cancer-detection-technology 2025-02-22T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persanta-advances-towards-ipo-with-dominari-securities-to-commercialize-early-cancer-detection-technology 2025-02-22T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-reports-strong-financial-growth-with-key-clinical-milestones-ahead-in-q1-2025 2025-02-22T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-reports-strong-financial-growth-with-key-clinical-milestones-ahead-in-q1-2025 2025-02-22T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-relvar-ellipta-demonstrates-superior-asthma-control-in-landmark-real-world-study 2025-02-22T05:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-relvar-ellipta-demonstrates-superior-asthma-control-in-landmark-real-world-study 2025-02-22T05:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/bay-2927088-shows-promise-in-her2-mutant-nsclc-with-high-response-rates-in-phase-i-ii-trial 2025-02-22T01:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bay-2927088-shows-promise-in-her2-mutant-nsclc-with-high-response-rates-in-phase-i-ii-trial 2025-02-22T01:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/sensyne-health-expands-global-patient-data-access-through-strategic-phesi-partnership-and-ps27-5m-fundraising 2025-02-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensyne-health-expands-global-patient-data-access-through-strategic-phesi-partnership-and-ps27-5m-fundraising 2025-02-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-halts-final-phase-3-keytruda-trial-in-prostate-cancer-after-failed-interim-analysis 2025-02-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-halts-final-phase-3-keytruda-trial-in-prostate-cancer-after-failed-interim-analysis 2025-02-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-phase-2-trial-of-revolutionary-bivacor-artificial-heart-device 2025-02-21T22:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-phase-2-trial-of-revolutionary-bivacor-artificial-heart-device 2025-02-21T22:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/pancan-study-completes-enrollment-of-8800-participants-to-investigate-diabetes-pancreatic-cancer-link 2025-02-21T22:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pancan-study-completes-enrollment-of-8800-participants-to-investigate-diabetes-pancreatic-cancer-link 2025-02-21T22:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/uromems-smart-urinary-sphincter-implant-achieves-primary-endpoints-in-pioneering-female-sui-study 2025-02-21T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uromems-smart-urinary-sphincter-implant-achieves-primary-endpoints-in-pioneering-female-sui-study 2025-02-21T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/verastem-oncology-to-present-new-lgsoc-treatment-data-at-sgo-2025-annual-meeting 2025-02-21T20:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verastem-oncology-to-present-new-lgsoc-treatment-data-at-sgo-2025-annual-meeting 2025-02-21T20:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/estrella-s-eb103-cell-therapy-shows-promising-safety-profile-in-nhl-trial-s-first-cohort 2025-02-21T19:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/estrella-s-eb103-cell-therapy-shows-promising-safety-profile-in-nhl-trial-s-first-cohort 2025-02-21T19:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/dsm-firmenich-s-solid-cbd-formulation-matches-epidiolex-s-bioavailability-in-clinical-study 2025-02-21T19:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dsm-firmenich-s-solid-cbd-formulation-matches-epidiolex-s-bioavailability-in-clinical-study 2025-02-21T19:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-mirum-s-chenodiol-tablets 2025-02-21T19:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-mirum-s-chenodiol-tablets 2025-02-21T19:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-compounds-nr-and-coq10-show-promise-in-improving-metabolism-and-reducing-inflammation-in-ckd-patients 2025-02-21T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-compounds-nr-and-coq10-show-promise-in-improving-metabolism-and-reducing-inflammation-in-ckd-patients 2025-02-21T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/novel-digital-cognitive-training-shows-promise-for-coronary-heart-disease-patients-in-clinical-trial 2025-02-21T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-digital-cognitive-training-shows-promise-for-coronary-heart-disease-patients-in-clinical-trial 2025-02-21T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-remote-ischemic-conditioning-protocol-shows-promise-in-protecting-heart-during-coronary-intervention 2025-02-21T19:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-remote-ischemic-conditioning-protocol-shows-promise-in-protecting-heart-during-coronary-intervention 2025-02-21T19:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-car-t-cell-trial-at-ben-taub-hospital-shows-promise-in-multiple-myeloma-treatment 2025-02-21T18:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-car-t-cell-trial-at-ben-taub-hospital-shows-promise-in-multiple-myeloma-treatment 2025-02-21T18:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-s-somerset-facility-receives-fda-establishment-inspection-report-confirming-compliance 2025-02-21T17:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-s-somerset-facility-receives-fda-establishment-inspection-report-confirming-compliance 2025-02-21T17:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/sera-prognostics-to-present-at-td-cowen-conference-and-report-q1-2025-results-in-may 2025-02-21T17:43:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sera-prognostics-to-present-at-td-cowen-conference-and-report-q1-2025-results-in-may 2025-02-21T17:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/kalvista-to-present-sebetralstat-data-at-major-medical-conferences-as-fda-review-continues 2025-02-21T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalvista-to-present-sebetralstat-data-at-major-medical-conferences-as-fda-review-continues 2025-02-21T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/phoenix-molecular-designs-initiates-phase-2-trial-of-pmd-026-combination-therapy-for-advanced-breast-cancer 2025-02-21T16:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phoenix-molecular-designs-initiates-phase-2-trial-of-pmd-026-combination-therapy-for-advanced-breast-cancer 2025-02-21T16:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/intensive-blood-pressure-control-shows-net-benefits-for-seniors-in-sprint-trial-analysis 2025-02-21T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensive-blood-pressure-control-shows-net-benefits-for-seniors-in-sprint-trial-analysis 2025-02-21T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-announces-kol-webcast-to-discuss-obefazimod-phase-3-trial-in-ulcerative-colitis 2025-02-21T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-announces-kol-webcast-to-discuss-obefazimod-phase-3-trial-in-ulcerative-colitis 2025-02-21T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-gene-therapy-restores-vision-in-children-with-rare-genetic-blindness 2025-02-21T16:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-gene-therapy-restores-vision-in-children-with-rare-genetic-blindness 2025-02-21T16:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/unmc-researcher-to-present-groundbreaking-icu-care-bundle-implementation-study-at-nih 2025-02-21T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unmc-researcher-to-present-groundbreaking-icu-care-bundle-implementation-study-at-nih 2025-02-21T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ctdna-assay-shows-high-predictive-value-for-breast-cancer-recurrence-during-neoadjuvant-therapy 2025-02-21T16:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ctdna-assay-shows-high-predictive-value-for-breast-cancer-recurrence-during-neoadjuvant-therapy 2025-02-21T16:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-launches-pioneering-gene-therapy-trial-for-cystic-fibrosis-treatment 2025-02-21T14:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-launches-pioneering-gene-therapy-trial-for-cystic-fibrosis-treatment 2025-02-21T14:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/head-to-head-study-shows-bimekizumab-outperforms-brodalumab-in-psoriasis-treatment 2025-02-21T13:46:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/head-to-head-study-shows-bimekizumab-outperforms-brodalumab-in-psoriasis-treatment 2025-02-21T13:46:37+00:00 hourly 0.9 https://trial.medpath.com/news/seikagaku-launches-phase-iii-trials-for-single-injection-osteoarthritis-treatment-in-japan 2025-02-21T13:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seikagaku-launches-phase-iii-trials-for-single-injection-osteoarthritis-treatment-in-japan 2025-02-21T13:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/ananda-pharma-achieves-gmp-manufacturing-milestone-for-mrx1-pain-treatment-program 2025-02-21T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ananda-pharma-achieves-gmp-manufacturing-milestone-for-mrx1-pain-treatment-program 2025-02-21T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antifungal-drug-fosmanogepix-enters-clinical-trials-at-westmead-hospital-for-drug-resistant-infections 2025-02-21T13:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antifungal-drug-fosmanogepix-enters-clinical-trials-at-westmead-hospital-for-drug-resistant-infections 2025-02-21T13:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hafnium-based-treatment-trial-launches-for-cisplatin-ineligible-head-and-neck-cancer-patients 2025-02-21T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hafnium-based-treatment-trial-launches-for-cisplatin-ineligible-head-and-neck-cancer-patients 2025-02-21T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-drug-amlodipine-shows-promise-as-novel-adhd-treatment-in-preclinical-study 2025-02-21T12:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-pressure-drug-amlodipine-shows-promise-as-novel-adhd-treatment-in-preclinical-study 2025-02-21T12:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-trials-comedy-on-prescription-as-novel-alternative-to-antidepressants 2025-02-21T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-trials-comedy-on-prescription-as-novel-alternative-to-antidepressants 2025-02-21T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/bantam-pharmaceutical-initiates-phase-1-trial-of-novel-mitochondrial-targeting-cancer-drug-at-md-anderson 2025-02-21T10:33:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bantam-pharmaceutical-initiates-phase-1-trial-of-novel-mitochondrial-targeting-cancer-drug-at-md-anderson 2025-02-21T10:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/lanifibranor-phase-1-trial-launches-in-japan-for-mash-treatment-development 2025-02-21T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lanifibranor-phase-1-trial-launches-in-japan-for-mash-treatment-development 2025-02-21T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-goes-private-in-29m-deal-with-carlyle-and-sk-capital-partners 2025-02-21T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluebird-bio-goes-private-in-29m-deal-with-carlyle-and-sk-capital-partners 2025-02-21T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-hyperview-revolutionary-x-ray-system-promises-3000-better-breast-cancer-detection 2025-02-21T09:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-hyperview-revolutionary-x-ray-system-promises-3000-better-breast-cancer-detection 2025-02-21T09:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-s-crd-38-shows-promise-in-heart-failure-treatment-with-novel-cannabidiol-approach 2025-02-21T08:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiol-s-crd-38-shows-promise-in-heart-failure-treatment-with-novel-cannabidiol-approach 2025-02-21T08:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-declares-end-to-ozempic-shortage-novo-nordisk-shares-surge-while-competitors-feel-impact 2025-02-21T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-declares-end-to-ozempic-shortage-novo-nordisk-shares-surge-while-competitors-feel-impact 2025-02-21T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-declares-end-to-ozempic-and-wegovy-shortages-as-novo-nordisk-ramps-up-supply 2025-02-21T08:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-declares-end-to-ozempic-and-wegovy-shortages-as-novo-nordisk-ramps-up-supply 2025-02-21T08:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/phoenix-molecular-advances-to-phase-ii-trial-testing-novel-breast-cancer-combination-therapy 2025-02-21T08:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phoenix-molecular-advances-to-phase-ii-trial-testing-novel-breast-cancer-combination-therapy 2025-02-21T08:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/prothena-s-birtamimab-shows-promise-in-phase-3-trial-for-al-amyloidosis-with-focus-on-high-risk-patients 2025-02-21T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prothena-s-birtamimab-shows-promise-in-phase-3-trial-for-al-amyloidosis-with-focus-on-high-risk-patients 2025-02-21T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/cerebrovascular-reactivity-emerges-as-key-biomarker-for-dementia-risk-and-cognitive-decline 2025-02-21T07:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerebrovascular-reactivity-emerges-as-key-biomarker-for-dementia-risk-and-cognitive-decline 2025-02-21T07:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-s-antibiotic-fetroja-receives-marketing-approval-in-south-korea-for-drug-resistant-infections 2025-02-21T07:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-s-antibiotic-fetroja-receives-marketing-approval-in-south-korea-for-drug-resistant-infections 2025-02-21T07:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-atreon-s-biocharge-matrix-for-rotator-cuff-repair 2025-02-21T06:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-atreon-s-biocharge-matrix-for-rotator-cuff-repair 2025-02-21T06:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/low-adoption-of-proven-neoadjuvant-chemotherapy-in-primary-urethral-cancer-raises-treatment-access-concerns 2025-02-21T06:55:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-adoption-of-proven-neoadjuvant-chemotherapy-in-primary-urethral-cancer-raises-treatment-access-concerns 2025-02-21T06:55:24+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-expert-highlights-evolution-of-sma-assessment-tools-and-treatment-outcomes-across-age-groups 2025-02-21T06:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-expert-highlights-evolution-of-sma-assessment-tools-and-treatment-outcomes-across-age-groups 2025-02-21T06:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/cns-drug-development-faces-rising-trial-failures-despite-innovation-surge 2025-02-21T04:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cns-drug-development-faces-rising-trial-failures-despite-innovation-surge 2025-02-21T04:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-discontinues-beqvez-gene-therapy-for-hemophilia-b-amid-low-market-demand 2025-02-21T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-discontinues-beqvez-gene-therapy-for-hemophilia-b-amid-low-market-demand 2025-02-21T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nevisense-ai-tool-significantly-improves-melanoma-biopsy-decisions-in-us-and-german-study 2025-02-21T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nevisense-ai-tool-significantly-improves-melanoma-biopsy-decisions-in-us-and-german-study 2025-02-21T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/symrise-partners-with-hbc-to-expand-marine-based-health-ingredients-portfolio 2025-02-21T02:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/symrise-partners-with-hbc-to-expand-marine-based-health-ingredients-portfolio 2025-02-21T02:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-acquires-fibrogen-china-for-160-million-strengthening-roxadustat-position 2025-02-21T02:01:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-acquires-fibrogen-china-for-160-million-strengthening-roxadustat-position 2025-02-21T02:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/celestial-and-cosmic-312-trials-shape-future-of-hcc-treatment-landscape 2025-02-21T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celestial-and-cosmic-312-trials-shape-future-of-hcc-treatment-landscape 2025-02-21T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/european-trial-launches-smart-screening-strategy-to-combat-rising-prostate-cancer-cases 2025-02-21T01:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-trial-launches-smart-screening-strategy-to-combat-rising-prostate-cancer-cases 2025-02-21T01:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/data-management-challenges-threaten-to-slow-precision-medicine-progress 2025-02-21T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/data-management-challenges-threaten-to-slow-precision-medicine-progress 2025-02-21T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-expands-market-presence-with-new-otcqb-listing-in-united-states 2025-02-21T00:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-expands-market-presence-with-new-otcqb-listing-in-united-states 2025-02-21T00:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-link-between-achr-antibody-levels-and-myasthenia-gravis-treatment-response 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-link-between-achr-antibody-levels-and-myasthenia-gravis-treatment-response 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-to-challenge-illumina-s-dominance-with-novel-sequencing-technology-launch-in-2024 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-to-challenge-illumina-s-dominance-with-novel-sequencing-technology-launch-in-2024 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/revitalvision-launches-fda-cleared-digital-vision-training-platform-for-adult-amblyopia-treatment 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revitalvision-launches-fda-cleared-digital-vision-training-platform-for-adult-amblyopia-treatment 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-faces-scrutiny-over-1m-stock-sale-amid-zolgensma-data-manipulation-investigation 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-faces-scrutiny-over-1m-stock-sale-amid-zolgensma-data-manipulation-investigation 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/wave-life-sciences-achieves-historic-milestone-with-first-human-rna-editing-data-in-aatd-treatment 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wave-life-sciences-achieves-historic-milestone-with-first-human-rna-editing-data-in-aatd-treatment 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/brukinsa-demonstrates-superior-safety-profile-compared-to-imbruvica-in-cll-treatment-study 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brukinsa-demonstrates-superior-safety-profile-compared-to-imbruvica-in-cll-treatment-study 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-historic-approval-to-biogen-s-qalsody-for-rare-genetic-form-of-als 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-historic-approval-to-biogen-s-qalsody-for-rare-genetic-form-of-als 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-reported-outcomes-and-real-world-data-reshape-treatment-landscape-in-cll-and-mcl 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-reported-outcomes-and-real-world-data-reshape-treatment-landscape-in-cll-and-mcl 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/luminal-a-dcis-shows-strong-response-to-letrozole-in-phase-ii-trial-genomic-study-reveals 2025-02-20T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luminal-a-dcis-shows-strong-response-to-letrozole-in-phase-ii-trial-genomic-study-reveals 2025-02-20T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/paxlovid-shows-limited-benefit-in-vaccinated-older-adults-ucla-study-finds 2025-02-20T22:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paxlovid-shows-limited-benefit-in-vaccinated-older-adults-ucla-study-finds 2025-02-20T22:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/dynavax-reports-strong-growth-with-heplisav-b-revenue-up-26-in-2024-advances-pipeline-programs 2025-02-20T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynavax-reports-strong-growth-with-heplisav-b-revenue-up-26-in-2024-advances-pipeline-programs 2025-02-20T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-revolutionizes-genomic-sequencing-with-novel-sequencing-by-expansion-technology 2025-02-20T19:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-revolutionizes-genomic-sequencing-with-novel-sequencing-by-expansion-technology 2025-02-20T19:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurona-s-nrtx-1001-cell-therapy-advances-to-phase-3-trial-for-drug-resistant-epilepsy 2025-02-20T19:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurona-s-nrtx-1001-cell-therapy-advances-to-phase-3-trial-for-drug-resistant-epilepsy 2025-02-20T19:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-zabalafin-hydrogel-ind-for-atopic-dermatitis-treatment-phase-2b-trials-to-begin-in-2025 2025-02-20T19:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-zabalafin-hydrogel-ind-for-atopic-dermatitis-treatment-phase-2b-trials-to-begin-in-2025 2025-02-20T19:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/novadip-s-novel-bone-graft-material-achieves-100-fracture-union-rate-in-phase-ib-iia-trial 2025-02-20T19:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novadip-s-novel-bone-graft-material-achieves-100-fracture-union-rate-in-phase-ib-iia-trial 2025-02-20T19:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-stim-device-trial-successfully-adapts-to-covid-19-challenges-in-depression-treatment-study 2025-02-20T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-stim-device-trial-successfully-adapts-to-covid-19-challenges-in-depression-treatment-study 2025-02-20T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-m-a-landscape-earnouts-dominate-deals-despite-low-success-rate-antitrust-scrutiny-intensifies 2025-02-20T18:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-m-a-landscape-earnouts-dominate-deals-despite-low-success-rate-antitrust-scrutiny-intensifies 2025-02-20T18:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-launches-first-in-class-inhaled-gene-therapy-trial-for-cystic-fibrosis 2025-02-20T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-launches-first-in-class-inhaled-gene-therapy-trial-for-cystic-fibrosis 2025-02-20T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/spanish-energyco-trial-to-evaluate-energy-expenditure-in-school-commuting-methods-and-cycling-intervention 2025-02-20T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spanish-energyco-trial-to-evaluate-energy-expenditure-in-school-commuting-methods-and-cycling-intervention 2025-02-20T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/eg-427-secures-eur27m-series-b-to-advance-novel-gene-therapy-for-spinal-cord-injury-related-bladder-dysfunction 2025-02-20T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eg-427-secures-eur27m-series-b-to-advance-novel-gene-therapy-for-spinal-cord-injury-related-bladder-dysfunction 2025-02-20T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-oxc-101-for-acute-myeloid-leukemia-treatment 2025-02-20T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-oxc-101-for-acute-myeloid-leukemia-treatment 2025-02-20T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/northsea-therapeutics-strengthens-executive-team-with-strategic-cfo-and-cmo-appointments 2025-02-20T16:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northsea-therapeutics-strengthens-executive-team-with-strategic-cfo-and-cmo-appointments 2025-02-20T16:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-major-discrepancies-in-cell-and-gene-therapy-trial-data-submitted-to-fda-and-ema 2025-02-20T16:33:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-major-discrepancies-in-cell-and-gene-therapy-trial-data-submitted-to-fda-and-ema 2025-02-20T16:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-casgevy-world-s-first-crispr-based-treatment-for-sickle-cell-disease 2025-02-20T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-casgevy-world-s-first-crispr-based-treatment-for-sickle-cell-disease 2025-02-20T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-s-imu-856-shows-promise-in-glp-1-elevation-and-weight-management-potential 2025-02-20T16:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunic-s-imu-856-shows-promise-in-glp-1-elevation-and-weight-management-potential 2025-02-20T16:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/vaxxas-advances-novel-microneedle-patch-delivery-for-h7n9-bird-flu-vaccine-in-phase-i-trial 2025-02-20T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxxas-advances-novel-microneedle-patch-delivery-for-h7n9-bird-flu-vaccine-in-phase-i-trial 2025-02-20T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/curasen-launches-phase-1-trial-of-curaax-for-neurogenic-orthostatic-hypotension-and-cognitive-impairment 2025-02-20T16:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curasen-launches-phase-1-trial-of-curaax-for-neurogenic-orthostatic-hypotension-and-cognitive-impairment 2025-02-20T16:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/peer-led-adhd-education-program-shows-promise-in-pilot-trial-for-newly-diagnosed-adults 2025-02-20T16:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peer-led-adhd-education-program-shows-promise-in-pilot-trial-for-newly-diagnosed-adults 2025-02-20T16:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/tambiciclib-zanubrutinib-combo-shows-67-response-rate-in-relapsed-refractory-dlbcl-trial 2025-02-20T16:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tambiciclib-zanubrutinib-combo-shows-67-response-rate-in-relapsed-refractory-dlbcl-trial 2025-02-20T16:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-semaglutide-to-increased-risk-of-vision-threatening-eye-condition 2025-02-20T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-semaglutide-to-increased-risk-of-vision-threatening-eye-condition 2025-02-20T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-status-to-skinte-for-diabetic-foot-ulcers 2025-02-20T15:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-status-to-skinte-for-diabetic-foot-ulcers 2025-02-20T15:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-depression-drug-spn-820-fails-to-meet-primary-endpoint-in-phase-iib-trial 2025-02-20T14:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supernus-depression-drug-spn-820-fails-to-meet-primary-endpoint-in-phase-iib-trial 2025-02-20T14:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-brtx-100-for-chronic-lumbar-disc-disease-treatment 2025-02-20T14:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-brtx-100-for-chronic-lumbar-disc-disease-treatment 2025-02-20T14:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-mrna-vaccines-show-promise-in-early-phase-pancreatic-cancer-trial 2025-02-20T14:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-mrna-vaccines-show-promise-in-early-phase-pancreatic-cancer-trial 2025-02-20T14:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/stifel-raises-price-target-on-trevi-therapeutics-as-haduvio-shows-promise-for-chronic-cough-treatment 2025-02-20T14:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stifel-raises-price-target-on-trevi-therapeutics-as-haduvio-shows-promise-for-chronic-cough-treatment 2025-02-20T14:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-shows-stable-ovarian-cancer-remission-rates-despite-covid-19-pandemic-disruptions 2025-02-20T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-shows-stable-ovarian-cancer-remission-rates-despite-covid-19-pandemic-disruptions 2025-02-20T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-patient-enrolled-in-aaa-shape-pivotal-trial-testing-novel-aneurysm-treatment 2025-02-20T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-european-patient-enrolled-in-aaa-shape-pivotal-trial-testing-novel-aneurysm-treatment 2025-02-20T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/seralutinib-shows-sustained-benefits-in-pah-responders-over-72-week-treatment-period 2025-02-20T13:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seralutinib-shows-sustained-benefits-in-pah-responders-over-72-week-treatment-period 2025-02-20T13:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/hemlibra-shows-significant-improvement-in-joint-pain-for-hemophilia-a-patients-in-78-week-study 2025-02-20T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemlibra-shows-significant-improvement-in-joint-pain-for-hemophilia-a-patients-in-78-week-study 2025-02-20T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-breakthrough-car-t-cell-therapy-liso-cel-for-advanced-lymphoma-patients 2025-02-20T13:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-approves-breakthrough-car-t-cell-therapy-liso-cel-for-advanced-lymphoma-patients 2025-02-20T13:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-combined-drug-therapy-shows-near-complete-elimination-of-liver-cancer-in-study 2025-02-20T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-combined-drug-therapy-shows-near-complete-elimination-of-liver-cancer-in-study 2025-02-20T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-weight-loss-in-retatrutide-trial-raises-safety-concerns-despite-efficacy 2025-02-20T13:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-weight-loss-in-retatrutide-trial-raises-safety-concerns-despite-efficacy 2025-02-20T13:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-brain-study-reveals-surprising-neurological-health-patterns-after-3-years 2025-02-20T13:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-brain-study-reveals-surprising-neurological-health-patterns-after-3-years 2025-02-20T13:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-expands-beyond-glp-1-success-targets-neurological-disease-breakthroughs 2025-02-20T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-expands-beyond-glp-1-success-targets-neurological-disease-breakthroughs 2025-02-20T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-s-alloseq-cfdna-test-shows-strong-performance-in-large-european-kidney-transplant-study 2025-02-20T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-s-alloseq-cfdna-test-shows-strong-performance-in-large-european-kidney-transplant-study 2025-02-20T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/trump-pressures-pharma-giants-reshore-manufacturing-or-face-tariffs 2025-02-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-pressures-pharma-giants-reshore-manufacturing-or-face-tariffs 2025-02-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-sanofi-s-rilzabrutinib-for-autoimmune-hemolytic-anemia 2025-02-20T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-sanofi-s-rilzabrutinib-for-autoimmune-hemolytic-anemia 2025-02-20T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-advances-cs1-development-program-with-fda-type-c-meeting-request-for-pah-treatment 2025-02-20T10:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cereno-scientific-advances-cs1-development-program-with-fda-type-c-meeting-request-for-pah-treatment 2025-02-20T10:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-s-ustekinumab-biosimilar-fyb202-shows-comparable-efficacy-to-stelara-r-in-clinical-studies 2025-02-20T10:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-s-ustekinumab-biosimilar-fyb202-shows-comparable-efficacy-to-stelara-r-in-clinical-studies 2025-02-20T10:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/ema-validates-aspaveli-r-extension-application-for-rare-kidney-diseases-c3g-and-ic-mpgn 2025-02-20T10:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-validates-aspaveli-r-extension-application-for-rare-kidney-diseases-c3g-and-ic-mpgn 2025-02-20T10:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/air-force-and-spark-biomedical-launch-trial-to-combat-motion-sickness-using-neurostimulation-technology 2025-02-20T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/air-force-and-spark-biomedical-launch-trial-to-combat-motion-sickness-using-neurostimulation-technology 2025-02-20T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/rheumatoid-arthritis-market-set-to-reach-34-7-billion-by-2035-driven-by-novel-therapies-and-rising-obesity-rates 2025-02-20T09:18:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rheumatoid-arthritis-market-set-to-reach-34-7-billion-by-2035-driven-by-novel-therapies-and-rising-obesity-rates 2025-02-20T09:18:36+00:00 hourly 0.9 https://trial.medpath.com/news/lucid-diagnostics-expands-esoguard-access-through-concierge-medicine-and-secures-first-commercial-insurance-coverage 2025-02-20T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lucid-diagnostics-expands-esoguard-access-through-concierge-medicine-and-secures-first-commercial-insurance-coverage 2025-02-20T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/urgent-need-for-pediatric-specific-rare-disease-treatments-as-30-die-before-age-five 2025-02-20T08:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urgent-need-for-pediatric-specific-rare-disease-treatments-as-30-die-before-age-five 2025-02-20T08:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/surgibox-secures-us-patents-for-portable-sterile-surgery-technology 2025-02-20T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgibox-secures-us-patents-for-portable-sterile-surgery-technology 2025-02-20T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-oxysterol-based-antibiotics-show-promise-against-drug-resistant-pathogens 2025-02-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-oxysterol-based-antibiotics-show-promise-against-drug-resistant-pathogens 2025-02-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anti-il23p19-therapies-transform-ibd-treatment-landscape-ahead-of-ecco-2025 2025-02-20T07:54:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anti-il23p19-therapies-transform-ibd-treatment-landscape-ahead-of-ecco-2025 2025-02-20T07:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/cognition-therapeutics-develops-enhanced-manufacturing-process-for-alzheimer-s-drug-candidate-zervimesine 2025-02-20T07:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognition-therapeutics-develops-enhanced-manufacturing-process-for-alzheimer-s-drug-candidate-zervimesine 2025-02-20T07:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-forges-strategic-ai-partnership-with-insilico-medicine-for-antibody-discovery 2025-02-20T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-forges-strategic-ai-partnership-with-insilico-medicine-for-antibody-discovery 2025-02-20T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-and-fda-align-on-phase-iii-program-for-irlab-s-mesdopetam-in-parkinson-s-disease 2025-02-20T07:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-and-fda-align-on-phase-iii-program-for-irlab-s-mesdopetam-in-parkinson-s-disease 2025-02-20T07:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/digital-home-based-copd-care-program-shows-61-reduction-in-hospital-readmissions 2025-02-20T07:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-home-based-copd-care-program-shows-61-reduction-in-hospital-readmissions 2025-02-20T07:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/mainz-biomed-partners-with-swiss-lab-to-launch-novel-colorectal-cancer-screening-test 2025-02-20T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainz-biomed-partners-with-swiss-lab-to-launch-novel-colorectal-cancer-screening-test 2025-02-20T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/siemens-to-raise-eur1-4-billion-through-strategic-healthineers-stake-sale 2025-02-20T07:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/siemens-to-raise-eur1-4-billion-through-strategic-healthineers-stake-sale 2025-02-20T07:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-safe-to-proceed-status-for-britecyte-s-novel-osteoarthritis-treatment 2025-02-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-safe-to-proceed-status-for-britecyte-s-novel-osteoarthritis-treatment 2025-02-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-amycretin-shows-promising-results-in-early-stage-clinical-trial 2025-02-20T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-amycretin-shows-promising-results-in-early-stage-clinical-trial 2025-02-20T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/managing-adverse-events-in-dlbcl-targeted-therapies-key-considerations-for-clinicians 2025-02-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/managing-adverse-events-in-dlbcl-targeted-therapies-key-considerations-for-clinicians 2025-02-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapy-combinations-show-promise-in-advanced-thymic-cancers 2025-02-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapy-combinations-show-promise-in-advanced-thymic-cancers 2025-02-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-layoffs-threaten-drug-safety-and-innovation-experts-warn-of-widespread-impact 2025-02-20T04:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-layoffs-threaten-drug-safety-and-innovation-experts-warn-of-widespread-impact 2025-02-20T04:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-s-phase-3-study-validates-yuflyma-s-interchangeability-with-humira-for-psoriasis-treatment 2025-02-20T04:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-s-phase-3-study-validates-yuflyma-s-interchangeability-with-humira-for-psoriasis-treatment 2025-02-20T04:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/cabozantinib-nivolumab-ipilimumab-combination-for-advanced-rcc-shows-sustained-benefits-with-critical-safety-considerations 2025-02-20T04:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabozantinib-nivolumab-ipilimumab-combination-for-advanced-rcc-shows-sustained-benefits-with-critical-safety-considerations 2025-02-20T04:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/global-pharma-launch-trends-2024-apac-markets-gain-ground-as-innovation-hubs 2025-02-20T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-pharma-launch-trends-2024-apac-markets-gain-ground-as-innovation-hubs 2025-02-20T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-mortality-rates-among-black-americans-show-decline-but-significant-disparities-persist 2025-02-20T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-mortality-rates-among-black-americans-show-decline-but-significant-disparities-persist 2025-02-20T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/treatment-com-ai-acquires-rocket-doctor-to-enhance-ai-powered-healthcare-platform 2025-02-20T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treatment-com-ai-acquires-rocket-doctor-to-enhance-ai-powered-healthcare-platform 2025-02-20T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-divests-50-stake-in-consumer-health-unit-supernus-depression-drug-falls-short-in-trial 2025-02-20T01:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-divests-50-stake-in-consumer-health-unit-supernus-depression-drug-falls-short-in-trial 2025-02-20T01:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/nih-study-evaluates-text-messaging-strategies-to-improve-cardiovascular-care-management 2025-02-20T01:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-study-evaluates-text-messaging-strategies-to-improve-cardiovascular-care-management 2025-02-20T01:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-therapy-designations-driving-pharmaceutical-market-to-reach-287-5-billion-by-2029 2025-02-20T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-therapy-designations-driving-pharmaceutical-market-to-reach-287-5-billion-by-2029 2025-02-20T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-variants-influence-success-of-smoking-cessation-drug-varenicline-landmark-study-finds 2025-02-20T00:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-variants-influence-success-of-smoking-cessation-drug-varenicline-landmark-study-finds 2025-02-20T00:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiance-biopharma-secures-1-2-billion-licensing-deal-for-novel-ror-1-targeted-cancer-therapy 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiance-biopharma-secures-1-2-billion-licensing-deal-for-novel-ror-1-targeted-cancer-therapy 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ezra-secures-fda-clearance-for-enhanced-full-body-mri-cancer-screening-technology 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ezra-secures-fda-clearance-for-enhanced-full-body-mri-cancer-screening-technology 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-analysis-reveals-85-drugs-in-development-for-metastatic-prostate-cancer-treatment 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-analysis-reveals-85-drugs-in-development-for-metastatic-prostate-cancer-treatment 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-to-launch-multi-cancer-vaccine-for-women-targeting-ages-9-16 2025-02-19T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-to-launch-multi-cancer-vaccine-for-women-targeting-ages-9-16 2025-02-19T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-immunitybio-authorization-to-supply-recombinant-bcg-amid-tice-bcg-shortage 2025-02-19T23:01:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-immunitybio-authorization-to-supply-recombinant-bcg-amid-tice-bcg-shortage 2025-02-19T23:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-saphnelo-secures-eu-approval-for-systemic-lupus-erythematosus-treatment 2025-02-19T23:01:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-saphnelo-secures-eu-approval-for-systemic-lupus-erythematosus-treatment 2025-02-19T23:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-transplantation-shows-promise-as-myeloid-directed-cellular-therapy-for-refractory-crohn-s-disease 2025-02-19T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-transplantation-shows-promise-as-myeloid-directed-cellular-therapy-for-refractory-crohn-s-disease 2025-02-19T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-refusal-to-file-for-pitolisant-in-idiopathic-hypersomnia-treatment 2025-02-19T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-refusal-to-file-for-pitolisant-in-idiopathic-hypersomnia-treatment 2025-02-19T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/navtemadlin-shows-promise-for-glioblastoma-treatment-when-combined-with-chemotherapy 2025-02-19T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navtemadlin-shows-promise-for-glioblastoma-treatment-when-combined-with-chemotherapy 2025-02-19T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-diversity-crisis-black-patients-severely-underrepresented-in-multiple-myeloma-studies 2025-02-19T20:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-diversity-crisis-black-patients-severely-underrepresented-in-multiple-myeloma-studies 2025-02-19T20:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/study-supports-safe-discontinuation-of-nivolumab-axitinib-therapy-in-responsive-metastatic-rcc-patients 2025-02-19T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-supports-safe-discontinuation-of-nivolumab-axitinib-therapy-in-responsive-metastatic-rcc-patients 2025-02-19T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/amplify-trial-shows-promise-acalabrutinib-combinations-outperform-chemoimmunotherapy-in-cll-sll-treatment 2025-02-19T19:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplify-trial-shows-promise-acalabrutinib-combinations-outperform-chemoimmunotherapy-in-cll-sll-treatment 2025-02-19T19:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-prime-designation-to-pioneer-lassa-fever-vaccine-marking-milestone-in-tropical-disease-prevention 2025-02-19T19:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-prime-designation-to-pioneer-lassa-fever-vaccine-marking-milestone-in-tropical-disease-prevention 2025-02-19T19:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-peluntamig-combination-therapy-trial-for-small-cell-lung-cancer 2025-02-19T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-peluntamig-combination-therapy-trial-for-small-cell-lung-cancer 2025-02-19T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-trueblue-trial-launches-to-revolutionize-postnatal-depression-detection 2025-02-19T19:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-trueblue-trial-launches-to-revolutionize-postnatal-depression-detection 2025-02-19T19:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/quality-of-life-studies-reveal-urban-rural-disparities-in-bladder-cancer-and-adt-impact-in-prostate-cancer-treatment 2025-02-19T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quality-of-life-studies-reveal-urban-rural-disparities-in-bladder-cancer-and-adt-impact-in-prostate-cancer-treatment 2025-02-19T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tesla-mri-head-coil-to-advance-lithium-brain-imaging-in-multiple-phase-ii-psychiatric-trials 2025-02-19T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tesla-mri-head-coil-to-advance-lithium-brain-imaging-in-multiple-phase-ii-psychiatric-trials 2025-02-19T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/anifrolumab-shows-60-reduction-in-organ-damage-progression-in-lupus-patients 2025-02-19T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anifrolumab-shows-60-reduction-in-organ-damage-progression-in-lupus-patients 2025-02-19T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-shows-promise-following-chemoradiotherapy-in-advanced-esophageal-cancer 2025-02-19T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-shows-promise-following-chemoradiotherapy-in-advanced-esophageal-cancer 2025-02-19T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-checkmate-816-trial-nivolumab-chemotherapy-combo-shows-survival-benefit-in-resectable-lung-cancer 2025-02-19T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-checkmate-816-trial-nivolumab-chemotherapy-combo-shows-survival-benefit-in-resectable-lung-cancer 2025-02-19T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-s-infoods-ibs-test-shows-significant-pain-reduction-in-clinical-trial-particularly-effective-for-ibs-c-and-ibs-m-patients 2025-02-19T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-s-infoods-ibs-test-shows-significant-pain-reduction-in-clinical-trial-particularly-effective-for-ibs-c-and-ibs-m-patients 2025-02-19T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-raises-545k-through-direct-stock-offering-to-advance-ai-driven-drug-discovery-platform 2025-02-19T14:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-raises-545k-through-direct-stock-offering-to-advance-ai-driven-drug-discovery-platform 2025-02-19T14:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-boehringer-s-zongertinib-for-her2-mutant-advanced-lung-cancer 2025-02-19T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-boehringer-s-zongertinib-for-her2-mutant-advanced-lung-cancer 2025-02-19T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/arcus-s-hif-2a-inhibitor-shows-promise-in-kidney-cancer-despite-gilead-s-exit 2025-02-19T13:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcus-s-hif-2a-inhibitor-shows-promise-in-kidney-cancer-despite-gilead-s-exit 2025-02-19T13:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-nv-387-shows-promise-against-multiple-viral-threats-following-successful-phase-i-trial 2025-02-19T13:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-nv-387-shows-promise-against-multiple-viral-threats-following-successful-phase-i-trial 2025-02-19T13:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aligns-with-chemomab-on-single-phase-3-trial-path-for-novel-psc-treatment-nebokitug 2025-02-19T13:31:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aligns-with-chemomab-on-single-phase-3-trial-path-for-novel-psc-treatment-nebokitug 2025-02-19T13:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/hemogenyx-secures-ps285000-funding-for-aml-car-t-trial-through-convertible-notes 2025-02-19T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemogenyx-secures-ps285000-funding-for-aml-car-t-trial-through-convertible-notes 2025-02-19T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-egfr-inhibitors-and-early-detection-dr-geoff-oxnard-bridges-clinical-practice-and-drug-development 2025-02-19T13:00:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-egfr-inhibitors-and-early-detection-dr-geoff-oxnard-bridges-clinical-practice-and-drug-development 2025-02-19T13:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-monoclonal-antibodies-market-projected-to-reach-284-9-billion-by-2034-growing-at-13-1-cagr 2025-02-19T12:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-monoclonal-antibodies-market-projected-to-reach-284-9-billion-by-2034-growing-at-13-1-cagr 2025-02-19T12:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/light-ai-s-ai-algorithm-shows-96-5-accuracy-in-strep-throat-detection-via-smartphone-images 2025-02-19T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-ai-s-ai-algorithm-shows-96-5-accuracy-in-strep-throat-detection-via-smartphone-images 2025-02-19T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-toothpaste-based-immunotherapy-shows-promise-for-peanut-allergy-treatment-in-phase-1-trial 2025-02-19T11:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-toothpaste-based-immunotherapy-shows-promise-for-peanut-allergy-treatment-in-phase-1-trial 2025-02-19T11:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-on-site-car-t-cell-manufacturing-promises-cost-reduction-and-improved-patient-access 2025-02-19T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-on-site-car-t-cell-manufacturing-promises-cost-reduction-and-improved-patient-access 2025-02-19T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-and-lilly-form-500m-alliance-to-develop-novel-bace-inhibitor-for-alzheimer-s-disease 2025-02-19T10:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-and-lilly-form-500m-alliance-to-develop-novel-bace-inhibitor-for-alzheimer-s-disease 2025-02-19T10:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmajet-s-needle-free-delivery-system-shows-promise-for-african-immunization-programs 2025-02-19T10:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmajet-s-needle-free-delivery-system-shows-promise-for-african-immunization-programs 2025-02-19T10:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/jord-bioscience-raises-series-b-funding-to-advance-agricultural-microbial-solutions 2025-02-19T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jord-bioscience-raises-series-b-funding-to-advance-agricultural-microbial-solutions 2025-02-19T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cmr-study-reveals-sex-specific-patterns-in-aortic-stenosis-women-show-better-survival-despite-similar-fibrosis-levels 2025-02-19T08:57:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cmr-study-reveals-sex-specific-patterns-in-aortic-stenosis-women-show-better-survival-despite-similar-fibrosis-levels 2025-02-19T08:57:22+00:00 hourly 0.9 https://trial.medpath.com/news/thetis-reports-positive-phase-1a-data-for-novel-ibd-drug-tp-317-demonstrating-blt1-target-engagement 2025-02-19T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thetis-reports-positive-phase-1a-data-for-novel-ibd-drug-tp-317-demonstrating-blt1-target-engagement 2025-02-19T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-staff-cuts-impact-neuralink-trial-review-team-amid-brain-implant-oversight 2025-02-19T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-staff-cuts-impact-neuralink-trial-review-team-amid-brain-implant-oversight 2025-02-19T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/essen-health-care-and-ownahealth-partner-to-revolutionize-diabetes-and-obesity-care-in-underserved-nyc-communities 2025-02-19T08:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essen-health-care-and-ownahealth-partner-to-revolutionize-diabetes-and-obesity-care-in-underserved-nyc-communities 2025-02-19T08:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/alcon-launches-voyager-dslt-revolutionary-automated-laser-treatment-for-glaucoma 2025-02-19T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alcon-launches-voyager-dslt-revolutionary-automated-laser-treatment-for-glaucoma 2025-02-19T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/sonnet-biotherapeutics-unveils-novel-adc-platform-for-enhanced-cancer-drug-development 2025-02-19T07:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonnet-biotherapeutics-unveils-novel-adc-platform-for-enhanced-cancer-drug-development 2025-02-19T07:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/hpq-silicon-patents-novel-one-step-process-for-advanced-li-ion-battery-cathode-materials 2025-02-19T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hpq-silicon-patents-novel-one-step-process-for-advanced-li-ion-battery-cathode-materials 2025-02-19T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/reverb-therapeutics-secures-12m-seed-funding-to-advance-novel-cytokine-targeting-platform 2025-02-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reverb-therapeutics-secures-12m-seed-funding-to-advance-novel-cytokine-targeting-platform 2025-02-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-s-vibativ-antibiotic-secures-chinese-nmpa-approval-for-severe-bacterial-infections 2025-02-19T06:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-s-vibativ-antibiotic-secures-chinese-nmpa-approval-for-severe-bacterial-infections 2025-02-19T06:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-workforce-crisis-drives-push-for-enhanced-collaboration-and-value-based-care 2025-02-19T05:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-workforce-crisis-drives-push-for-enhanced-collaboration-and-value-based-care 2025-02-19T05:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-ons-5010-bla-resubmission-progresses-amid-price-target-adjustment 2025-02-19T05:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-therapeutics-ons-5010-bla-resubmission-progresses-amid-price-target-adjustment 2025-02-19T05:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-secures-new-financing-through-at-market-direct-offering 2025-02-19T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-secures-new-financing-through-at-market-direct-offering 2025-02-19T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amazon-and-msk-cancer-center-partner-to-accelerate-ai-driven-drug-discovery 2025-02-19T04:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amazon-and-msk-cancer-center-partner-to-accelerate-ai-driven-drug-discovery 2025-02-19T04:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-neuren-s-novel-pitt-hopkins-syndrome-treatment 2025-02-19T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-neuren-s-novel-pitt-hopkins-syndrome-treatment 2025-02-19T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/septerna-halts-phase-1-trial-of-sep-786-for-hypoparathyroidism-due-to-safety-concerns 2025-02-19T04:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/septerna-halts-phase-1-trial-of-sep-786-for-hypoparathyroidism-due-to-safety-concerns 2025-02-19T04:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/scleroderma-autoantibody-types-influence-disease-progression-and-clinical-trial-outcomes 2025-02-19T04:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scleroderma-autoantibody-types-influence-disease-progression-and-clinical-trial-outcomes 2025-02-19T04:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/better-choice-company-divests-halo-asia-operations-in-8-1-million-strategic-sale 2025-02-19T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/better-choice-company-divests-halo-asia-operations-in-8-1-million-strategic-sale 2025-02-19T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-ceo-launches-250k-pre-seed-fund-to-counter-nih-funding-cuts 2025-02-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-ceo-launches-250k-pre-seed-fund-to-counter-nih-funding-cuts 2025-02-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-advances-phase-2-alzheimer-s-trial-with-igc-ad1-reports-26-revenue-growth-in-q3-2025 2025-02-19T02:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-advances-phase-2-alzheimer-s-trial-with-igc-ad1-reports-26-revenue-growth-in-q3-2025 2025-02-19T02:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/imagion-biosystems-initiates-manufacturing-of-magsense-her2-imaging-agent-for-fda-application 2025-02-19T02:21:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagion-biosystems-initiates-manufacturing-of-magsense-her2-imaging-agent-for-fda-application 2025-02-19T02:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-complexity-drives-30-cost-increase-industry-faces-growing-challenges-in-drug-development 2025-02-19T02:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-complexity-drives-30-cost-increase-industry-faces-growing-challenges-in-drug-development 2025-02-19T02:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-files-830m-fraud-lawsuit-against-kbp-biosciences-over-failed-kidney-drug 2025-02-19T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-files-830m-fraud-lawsuit-against-kbp-biosciences-over-failed-kidney-drug 2025-02-19T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/rosuvastatin-trial-launches-to-enhance-rectal-cancer-treatment-response 2025-02-19T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rosuvastatin-trial-launches-to-enhance-rectal-cancer-treatment-response 2025-02-19T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/netramark-to-present-ai-powered-clinical-trial-analysis-tools-for-psychiatric-disorders-at-isctm-meeting 2025-02-19T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/netramark-to-present-ai-powered-clinical-trial-analysis-tools-for-psychiatric-disorders-at-isctm-meeting 2025-02-19T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-completes-eur10-billion-sale-of-opella-to-cd-r-transforms-into-pure-play-biopharma 2025-02-19T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-completes-eur10-billion-sale-of-opella-to-cd-r-transforms-into-pure-play-biopharma 2025-02-19T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/tepezza-sales-surge-as-thyroid-eye-disease-treatment-market-expands-to-2-3-billion 2025-02-19T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tepezza-sales-surge-as-thyroid-eye-disease-treatment-market-expands-to-2-3-billion 2025-02-19T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/pirtobrutinib-shows-superior-efficacy-in-btk-inhibitor-pretreated-cll-patients 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pirtobrutinib-shows-superior-efficacy-in-btk-inhibitor-pretreated-cll-patients 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-community-health-workers-unite-to-transform-clinical-trial-access-and-skin-cancer-care 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-community-health-workers-unite-to-transform-clinical-trial-access-and-skin-cancer-care 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-sponge-like-implant-and-nanoparticle-therapy-shows-promise-in-multiple-sclerosis-treatment 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-sponge-like-implant-and-nanoparticle-therapy-shows-promise-in-multiple-sclerosis-treatment 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/epitopea-and-msd-partner-in-300m-deal-to-develop-novel-cancer-immunotherapies-using-junk-dna-antigens 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epitopea-and-msd-partner-in-300m-deal-to-develop-novel-cancer-immunotherapies-using-junk-dna-antigens 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/finland-achieves-major-breakthrough-in-ms-treatment-diagnosis-time-cut-in-half-over-past-decade 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/finland-achieves-major-breakthrough-in-ms-treatment-diagnosis-time-cut-in-half-over-past-decade 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-vyjuvek-breakthrough-topical-gene-therapy-for-dystrophic-epidermolysis-bullosa 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-vyjuvek-breakthrough-topical-gene-therapy-for-dystrophic-epidermolysis-bullosa 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitors-show-promising-efficacy-in-alopecia-areata-treatment-according-to-meta-analysis 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitors-show-promising-efficacy-in-alopecia-areata-treatment-according-to-meta-analysis 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-astrazeneca-s-fasenra-for-nasal-polyp-treatment-additional-clinical-data-required 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-astrazeneca-s-fasenra-for-nasal-polyp-treatment-additional-clinical-data-required 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-to-participate-in-major-healthcare-investor-conferences-in-may-june-2025 2025-02-18T22:54:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-to-participate-in-major-healthcare-investor-conferences-in-may-june-2025 2025-02-18T22:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-initiates-phase-2-study-with-fast-track-potential 2025-02-18T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-initiates-phase-2-study-with-fast-track-potential 2025-02-18T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/protocol-amendment-expands-anixa-s-ovarian-cancer-car-t-trial-second-dosing-and-new-cancer-types-added 2025-02-18T22:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protocol-amendment-expands-anixa-s-ovarian-cancer-car-t-trial-second-dosing-and-new-cancer-types-added 2025-02-18T22:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-blood-test-for-early-ovarian-cancer-detection-enters-clinical-trials-in-australia 2025-02-18T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-blood-test-for-early-ovarian-cancer-detection-enters-clinical-trials-in-australia 2025-02-18T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-secures-indian-patent-for-novel-liposomal-cbd-pain-treatment-platform 2025-02-18T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocan-pharma-secures-indian-patent-for-novel-liposomal-cbd-pain-treatment-platform 2025-02-18T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/purple-biotech-launches-phase-2-trial-of-nt219-for-drug-resistant-head-and-neck-cancer 2025-02-18T20:01:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purple-biotech-launches-phase-2-trial-of-nt219-for-drug-resistant-head-and-neck-cancer 2025-02-18T20:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-introduces-revolutionary-emergency-department-nerve-block-tray-to-reduce-opioid-use 2025-02-18T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-braun-introduces-revolutionary-emergency-department-nerve-block-tray-to-reduce-opioid-use 2025-02-18T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-validates-rituximab-lenalidomide-efficacy-in-indolent-non-hodgkin-lymphoma-treatment 2025-02-18T19:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-validates-rituximab-lenalidomide-efficacy-in-indolent-non-hodgkin-lymphoma-treatment 2025-02-18T19:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/voiant-s-imaging-endpoints-support-fda-approval-of-new-treatments-for-colorectal-cancer-and-glioma 2025-02-18T19:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voiant-s-imaging-endpoints-support-fda-approval-of-new-treatments-for-colorectal-cancer-and-glioma 2025-02-18T19:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-plans-fda-submission-for-hugo-surgical-robot-eyes-us-launch-in-fy2026 2025-02-18T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-plans-fda-submission-for-hugo-surgical-robot-eyes-us-launch-in-fy2026 2025-02-18T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/opus-genetics-advances-lca5-gene-therapy-program-with-first-pediatric-patient-dosing-and-promising-adult-data 2025-02-18T19:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opus-genetics-advances-lca5-gene-therapy-program-with-first-pediatric-patient-dosing-and-promising-adult-data 2025-02-18T19:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/ucsd-to-evaluate-nexalin-s-halo-device-for-ptsd-and-brain-injury-treatment-in-independent-clinical-trial 2025-02-18T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsd-to-evaluate-nexalin-s-halo-device-for-ptsd-and-brain-injury-treatment-in-independent-clinical-trial 2025-02-18T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/life-spine-s-gruve-cervical-plating-system-receives-fda-clearance-for-spinal-surgery 2025-02-18T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-spine-s-gruve-cervical-plating-system-receives-fda-clearance-for-spinal-surgery 2025-02-18T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/northstrive-biosciences-seeks-fda-guidance-for-novel-muscle-preserving-obesity-treatment-el-22 2025-02-18T17:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northstrive-biosciences-seeks-fda-guidance-for-novel-muscle-preserving-obesity-treatment-el-22 2025-02-18T17:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/novel-at-home-type-1-diabetes-test-could-transform-pediatric-diagnosis-in-uk-nhs-study 2025-02-18T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-at-home-type-1-diabetes-test-could-transform-pediatric-diagnosis-in-uk-nhs-study 2025-02-18T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/ventyx-s-vtx958-shows-promising-endoscopic-response-in-phase-2-crohn-s-disease-trial-despite-missing-primary-endpoint 2025-02-18T16:36:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventyx-s-vtx958-shows-promising-endoscopic-response-in-phase-2-crohn-s-disease-trial-despite-missing-primary-endpoint 2025-02-18T16:36:33+00:00 hourly 0.9 https://trial.medpath.com/news/algotx-s-phase-2-cipn-trial-shows-promise-for-atx01-despite-placebo-effect-challenges 2025-02-18T16:36:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algotx-s-phase-2-cipn-trial-shows-promise-for-atx01-despite-placebo-effect-challenges 2025-02-18T16:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/parazero-s-precision-airdrop-system-advances-to-phase-ii-defense-testing-for-critical-medical-supply-delivery 2025-02-18T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parazero-s-precision-airdrop-system-advances-to-phase-ii-defense-testing-for-critical-medical-supply-delivery 2025-02-18T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/namodenoson-shows-promise-in-treating-decompensated-liver-cirrhosis-patient-s-remarkable-recovery-in-compassionate-use-program 2025-02-18T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/namodenoson-shows-promise-in-treating-decompensated-liver-cirrhosis-patient-s-remarkable-recovery-in-compassionate-use-program 2025-02-18T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-therapeutics-reports-strong-growth-with-88-revenue-increase-in-2024-advances-cns-pipeline 2025-02-18T16:35:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axsome-therapeutics-reports-strong-growth-with-88-revenue-increase-in-2024-advances-cns-pipeline 2025-02-18T16:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-bonus-biogroup-s-phase-iii-trial-for-novel-ards-treatment 2025-02-18T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-bonus-biogroup-s-phase-iii-trial-for-novel-ards-treatment 2025-02-18T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/tivumecirnon-keytruda-combination-shows-promise-in-ebv-positive-gastric-cancer-trial 2025-02-18T16:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivumecirnon-keytruda-combination-shows-promise-in-ebv-positive-gastric-cancer-trial 2025-02-18T16:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-to-present-new-briumvi-data-in-multiple-sclerosis-at-actrims-2025-forum 2025-02-18T16:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-therapeutics-to-present-new-briumvi-data-in-multiple-sclerosis-at-actrims-2025-forum 2025-02-18T16:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-s-rese-cel-shows-promising-results-in-multiple-autoimmune-diseases-achieving-drug-free-remission 2025-02-18T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabaletta-bio-s-rese-cel-shows-promising-results-in-multiple-autoimmune-diseases-achieving-drug-free-remission 2025-02-18T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/extracellular-vesicles-emerge-as-revolutionary-platform-for-large-scale-biomanufacturing-and-clinical-applications 2025-02-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extracellular-vesicles-emerge-as-revolutionary-platform-for-large-scale-biomanufacturing-and-clinical-applications 2025-02-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-s-ai-platform-accelerates-cancer-drug-discovery-outperforming-standard-treatment 2025-02-18T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-s-ai-platform-accelerates-cancer-drug-discovery-outperforming-standard-treatment 2025-02-18T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-minnesota-launches-groundbreaking-vaccine-trial-for-deadly-pediatric-brain-cancer 2025-02-18T14:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/children-s-minnesota-launches-groundbreaking-vaccine-trial-for-deadly-pediatric-brain-cancer 2025-02-18T14:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/pillar-biosciences-and-hamilton-partner-to-automate-ngs-testing-with-advanced-liquid-handling-systems 2025-02-18T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pillar-biosciences-and-hamilton-partner-to-automate-ngs-testing-with-advanced-liquid-handling-systems 2025-02-18T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/optyx-study-patients-and-physicians-prefer-oral-relugolix-over-injectable-adt-for-advanced-prostate-cancer 2025-02-18T14:02:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optyx-study-patients-and-physicians-prefer-oral-relugolix-over-injectable-adt-for-advanced-prostate-cancer 2025-02-18T14:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-gap-in-advanced-prostate-cancer-treatment-adoption-between-academic-and-community-physicians 2025-02-18T14:01:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-gap-in-advanced-prostate-cancer-treatment-adoption-between-academic-and-community-physicians 2025-02-18T14:01:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-second-breakthrough-therapy-designation-for-petosemtamab-in-head-and-neck-cancer 2025-02-18T14:01:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-second-breakthrough-therapy-designation-for-petosemtamab-in-head-and-neck-cancer 2025-02-18T14:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-to-dupixent-for-bullous-pemphigoid-treatment 2025-02-18T13:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-dupixent-for-bullous-pemphigoid-treatment 2025-02-18T13:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-s-dr-vivek-reddy-to-lead-orchestra-biomed-s-backbeat-study-as-executive-chairman 2025-02-18T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-s-dr-vivek-reddy-to-lead-orchestra-biomed-s-backbeat-study-as-executive-chairman 2025-02-18T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-and-biomarker-driven-approaches-transform-sarcoma-treatment-landscape 2025-02-18T11:59:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-and-biomarker-driven-approaches-transform-sarcoma-treatment-landscape 2025-02-18T11:59:29+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-gene-therapy-market-projected-to-reach-22-23-billion-by-2034-growing-at-19-8-cagr 2025-02-18T11:45:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-gene-therapy-market-projected-to-reach-22-23-billion-by-2034-growing-at-19-8-cagr 2025-02-18T11:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/preoperative-immunonutritional-status-emerges-as-critical-predictor-of-ovarian-cancer-outcomes-in-large-chinese-study 2025-02-18T11:00:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preoperative-immunonutritional-status-emerges-as-critical-predictor-of-ovarian-cancer-outcomes-in-large-chinese-study 2025-02-18T11:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-navi-medical-s-groundbreaking-ecg-tip-location-system-for-neonatal-central-line-placement 2025-02-18T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-navi-medical-s-groundbreaking-ecg-tip-location-system-for-neonatal-central-line-placement 2025-02-18T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-secures-japan-s-first-adhd-digital-therapeutic-approval-with-endeavorride 2025-02-18T10:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-secures-japan-s-first-adhd-digital-therapeutic-approval-with-endeavorride 2025-02-18T10:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-study-reveals-silent-spread-of-h5n1-bird-flu-among-veterinarians-as-new-strains-emerge 2025-02-18T10:25:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-study-reveals-silent-spread-of-h5n1-bird-flu-among-veterinarians-as-new-strains-emerge 2025-02-18T10:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/vaxxas-advances-revolutionary-needle-free-vaccine-patch-in-largest-hd-map-clinical-trial 2025-02-18T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxxas-advances-revolutionary-needle-free-vaccine-patch-in-largest-hd-map-clinical-trial 2025-02-18T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/endovascular-engineering-secures-42m-series-b-to-advance-novel-pulmonary-embolism-treatment 2025-02-18T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endovascular-engineering-secures-42m-series-b-to-advance-novel-pulmonary-embolism-treatment 2025-02-18T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-advocacy-groups-lead-fight-against-colorectal-cancer-care-disparities-takeda-study-reveals 2025-02-18T09:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-advocacy-groups-lead-fight-against-colorectal-cancer-care-disparities-takeda-study-reveals 2025-02-18T09:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/aidoc-s-foundation-model-powered-ai-for-rib-fracture-detection-receives-fda-clearance 2025-02-18T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aidoc-s-foundation-model-powered-ai-for-rib-fracture-detection-receives-fda-clearance 2025-02-18T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/syrenity-mental-health-app-shows-promise-in-reducing-depression-symptoms-in-indiana-university-study 2025-02-18T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syrenity-mental-health-app-shows-promise-in-reducing-depression-symptoms-in-indiana-university-study 2025-02-18T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/thykaminetm-shows-promising-anti-fibrotic-effects-through-significant-gene-expression-changes-in-preclinical-study 2025-02-18T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thykaminetm-shows-promising-anti-fibrotic-effects-through-significant-gene-expression-changes-in-preclinical-study 2025-02-18T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/combination-immunotherapy-achieves-51-seven-year-survival-rate-in-advanced-melanoma-brain-metastases 2025-02-18T08:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-immunotherapy-achieves-51-seven-year-survival-rate-in-advanced-melanoma-brain-metastases 2025-02-18T08:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/allurion-to-study-combined-glp-1-and-gastric-balloon-therapy-for-enhanced-obesity-treatment 2025-02-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allurion-to-study-combined-glp-1-and-gastric-balloon-therapy-for-enhanced-obesity-treatment 2025-02-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-secures-eu-approval-for-denosumab-biosimilars-targeting-osteoporosis-and-cancer-complications 2025-02-18T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-secures-eu-approval-for-denosumab-biosimilars-targeting-osteoporosis-and-cancer-complications 2025-02-18T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-raises-5-7m-to-advance-novel-radiotherapy-for-leptomeningeal-metastases 2025-02-18T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plus-therapeutics-raises-5-7m-to-advance-novel-radiotherapy-for-leptomeningeal-metastases 2025-02-18T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/heartsense-uncovers-hidden-cardiovascular-disease-burden-in-underserved-communities 2025-02-18T07:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartsense-uncovers-hidden-cardiovascular-disease-burden-in-underserved-communities 2025-02-18T07:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-renews-commitment-to-single-cell-data-science-consortium-for-phase-2 2025-02-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-renews-commitment-to-single-cell-data-science-consortium-for-phase-2 2025-02-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-major-disparities-in-us-health-insurance-coverage-for-pharmacogenetic-testing 2025-02-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-major-disparities-in-us-health-insurance-coverage-for-pharmacogenetic-testing 2025-02-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/harper-health-partners-with-opendna-to-launch-ai-powered-genetic-screening-services 2025-02-18T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harper-health-partners-with-opendna-to-launch-ai-powered-genetic-screening-services 2025-02-18T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-confirms-strong-immune-response-to-two-dose-meningococcal-vaccine-series-in-adolescents 2025-02-18T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-confirms-strong-immune-response-to-two-dose-meningococcal-vaccine-series-in-adolescents 2025-02-18T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/hanchorbio-s-hcb101-advances-in-clinical-trials-leading-novel-cd47-targeting-immunotherapy-pipeline 2025-02-18T04:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanchorbio-s-hcb101-advances-in-clinical-trials-leading-novel-cd47-targeting-immunotherapy-pipeline 2025-02-18T04:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ono-pharmaceutical-s-novel-therapy-for-tgct-expanding-treatment-options 2025-02-18T04:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ono-pharmaceutical-s-novel-therapy-for-tgct-expanding-treatment-options 2025-02-18T04:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-launches-15-year-hesperia-study-to-track-long-term-outcomes-of-car-t-therapies 2025-02-18T01:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-launches-15-year-hesperia-study-to-track-long-term-outcomes-of-car-t-therapies 2025-02-18T01:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/new-trials-challenge-thrombectomy-benefits-for-medium-and-distal-vessel-stroke 2025-02-18T01:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-trials-challenge-thrombectomy-benefits-for-medium-and-distal-vessel-stroke 2025-02-18T01:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/uk-life-sciences-sector-faces-manufacturing-gap-despite-research-excellence 2025-02-18T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-life-sciences-sector-faces-manufacturing-gap-despite-research-excellence 2025-02-18T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-legislation-proposes-ai-systems-as-legal-drug-prescribers 2025-02-18T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-legislation-proposes-ai-systems-as-legal-drug-prescribers 2025-02-18T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-injectable-gallium-based-paste-shows-promise-for-revolutionary-bone-cancer-treatment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-injectable-gallium-based-paste-shows-promise-for-revolutionary-bone-cancer-treatment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-statins-boost-effectiveness-of-cancer-immunotherapy 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-reveals-statins-boost-effectiveness-of-cancer-immunotherapy 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-tightens-requirements-for-china-developed-drugs-mandates-multi-regional-trials 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-tightens-requirements-for-china-developed-drugs-mandates-multi-regional-trials 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-confirms-sugammadex-s-safety-and-efficacy-in-myasthenia-gravis-patients-post-surgery 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-confirms-sugammadex-s-safety-and-efficacy-in-myasthenia-gravis-patients-post-surgery 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-cognition-advances-digital-assessment-tool-for-schizophrenia-related-cognitive-impairment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-cognition-advances-digital-assessment-tool-for-schizophrenia-related-cognitive-impairment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/loqus23-therapeutics-names-industry-veteran-cyrus-mozayeni-as-board-chair-following-ps35m-series-a 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/loqus23-therapeutics-names-industry-veteran-cyrus-mozayeni-as-board-chair-following-ps35m-series-a 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/lisdexamfetamine-shows-variable-efficacy-in-binge-eating-disorder-treatment-rutgers-study-finds 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisdexamfetamine-shows-variable-efficacy-in-binge-eating-disorder-treatment-rutgers-study-finds 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-blood-test-breakthrough-promises-less-invasive-monitoring-for-childhood-cancer-treatment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-blood-test-breakthrough-promises-less-invasive-monitoring-for-childhood-cancer-treatment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/septerna-halts-phase-i-trial-of-hypoparathyroidism-drug-sep-786-due-to-safety-concerns 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/septerna-halts-phase-i-trial-of-hypoparathyroidism-drug-sep-786-due-to-safety-concerns 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-secures-global-rights-to-novel-dravet-syndrome-treatment-in-550m-deal 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-secures-global-rights-to-novel-dravet-syndrome-treatment-in-550m-deal 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/uthealth-houston-pioneers-telerehabilitation-trial-for-underserved-stroke-patients-in-rio-grande-valley 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uthealth-houston-pioneers-telerehabilitation-trial-for-underserved-stroke-patients-in-rio-grande-valley 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lilly-s-retevmo-as-first-targeted-therapy-for-ret-positive-lung-and-thyroid-cancers 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lilly-s-retevmo-as-first-targeted-therapy-for-ret-positive-lung-and-thyroid-cancers 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-takeda-s-exkivity-as-first-oral-therapy-for-egfr-exon20-nsclc 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-takeda-s-exkivity-as-first-oral-therapy-for-egfr-exon20-nsclc 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-grass-pollen-immunotherapy-shows-superior-20-3-symptom-reduction-in-landmark-phase-3-trial 2025-02-17T22:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-grass-pollen-immunotherapy-shows-superior-20-3-symptom-reduction-in-landmark-phase-3-trial 2025-02-17T22:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-sod1-targeting-drug-qalsody-shows-unprecedented-improvement-in-genetic-als-patients 2025-02-17T22:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-sod1-targeting-drug-qalsody-shows-unprecedented-improvement-in-genetic-als-patients 2025-02-17T22:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/teriparatide-biosimilar-rgb-10-demonstrates-equivalent-efficacy-to-reference-drug-in-high-risk-osteoporosis-patients 2025-02-17T22:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teriparatide-biosimilar-rgb-10-demonstrates-equivalent-efficacy-to-reference-drug-in-high-risk-osteoporosis-patients 2025-02-17T22:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-18-year-remission-achieved-in-neuroblastoma-patient-following-car-t-cell-therapy 2025-02-17T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-18-year-remission-achieved-in-neuroblastoma-patient-following-car-t-cell-therapy 2025-02-17T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/novel-treatment-approaches-show-promise-in-brain-cancer-from-aerosolized-drugs-to-personalized-vaccines 2025-02-17T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-treatment-approaches-show-promise-in-brain-cancer-from-aerosolized-drugs-to-personalized-vaccines 2025-02-17T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/fragile-x-syndrome-market-set-for-83-2m-growth-with-novel-therapeutic-approaches 2025-02-17T20:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fragile-x-syndrome-market-set-for-83-2m-growth-with-novel-therapeutic-approaches 2025-02-17T20:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-screening-doubles-enrollment-rate-in-heart-failure-clinical-trial 2025-02-17T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-screening-doubles-enrollment-rate-in-heart-failure-clinical-trial 2025-02-17T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-direct-to-consumer-genetic-test-for-celiac-disease-risk 2025-02-17T18:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-direct-to-consumer-genetic-test-for-celiac-disease-risk 2025-02-17T18:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-halts-phase-iii-trial-of-fyb206-following-fda-feedback-faces-market-challenges-for-biosimilars 2025-02-17T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-halts-phase-iii-trial-of-fyb206-following-fda-feedback-faces-market-challenges-for-biosimilars 2025-02-17T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-bcl2-inhibitor-icp-248-combination-therapy-advances-to-phase-iii-trial-for-first-line-cll-sll-treatment-in-china 2025-02-17T16:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-bcl2-inhibitor-icp-248-combination-therapy-advances-to-phase-iii-trial-for-first-line-cll-sll-treatment-in-china 2025-02-17T16:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/vivistim-vns-therapy-shows-promising-real-world-outcomes-in-chronic-stroke-recovery 2025-02-17T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivistim-vns-therapy-shows-promising-real-world-outcomes-in-chronic-stroke-recovery 2025-02-17T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-terzo-trial-to-evaluate-duvelisib-in-rare-t-cell-lymphoma-following-promising-phase-2-results 2025-02-17T16:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-terzo-trial-to-evaluate-duvelisib-in-rare-t-cell-lymphoma-following-promising-phase-2-results 2025-02-17T16:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/istesso-s-leramistat-misses-primary-endpoint-in-phase-2b-rheumatoid-arthritis-trial-shows-promise-in-bone-protection 2025-02-17T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/istesso-s-leramistat-misses-primary-endpoint-in-phase-2b-rheumatoid-arthritis-trial-shows-promise-in-bone-protection 2025-02-17T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/swissmedic-and-swissethics-release-new-guidelines-for-decentralized-clinical-trials 2025-02-17T16:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swissmedic-and-swissethics-release-new-guidelines-for-decentralized-clinical-trials 2025-02-17T16:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/bladder-preserving-treatment-shows-promise-radiation-plus-dual-immunotherapy-achieves-93-complete-response-in-mibc 2025-02-17T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bladder-preserving-treatment-shows-promise-radiation-plus-dual-immunotherapy-achieves-93-complete-response-in-mibc 2025-02-17T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-partners-with-maxcyte-to-advance-novel-car-t-cell-therapy-for-progressive-ms 2025-02-17T16:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-therapeutics-partners-with-maxcyte-to-advance-novel-car-t-cell-therapy-for-progressive-ms 2025-02-17T16:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-s-myostatin-blocking-antibody-advances-to-fda-review-for-spinal-muscular-atrophy 2025-02-17T16:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-s-myostatin-blocking-antibody-advances-to-fda-review-for-spinal-muscular-atrophy 2025-02-17T16:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/icc-tribunal-rules-in-aop-health-s-favor-over-besremi-licensing-dispute-with-pharmaessentia 2025-02-17T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icc-tribunal-rules-in-aop-health-s-favor-over-besremi-licensing-dispute-with-pharmaessentia 2025-02-17T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/psma-targeted-therapies-transform-prostate-cancer-treatment-landscape 2025-02-17T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psma-targeted-therapies-transform-prostate-cancer-treatment-landscape 2025-02-17T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/leramistat-shows-promise-in-bone-protection-for-rheumatoid-arthritis-despite-missing-primary-endpoint 2025-02-17T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leramistat-shows-promise-in-bone-protection-for-rheumatoid-arthritis-despite-missing-primary-endpoint 2025-02-17T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/in8bio-s-inb-100-shows-promising-phase-1-results-with-zero-relapses-in-high-risk-aml-patients 2025-02-17T13:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in8bio-s-inb-100-shows-promising-phase-1-results-with-zero-relapses-in-high-risk-aml-patients 2025-02-17T13:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/12-month-study-shows-promising-safety-and-efficacy-of-esmethadone-for-major-depression 2025-02-17T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/12-month-study-shows-promising-safety-and-efficacy-of-esmethadone-for-major-depression 2025-02-17T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/bambusa-therapeutics-secures-90m-series-a-to-advance-novel-bispecific-antibody-pipeline 2025-02-17T13:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bambusa-therapeutics-secures-90m-series-a-to-advance-novel-bispecific-antibody-pipeline 2025-02-17T13:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/guard-therapeutics-announces-sek-150m-rights-issue-to-advance-kidney-protection-drug-development 2025-02-17T13:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guard-therapeutics-announces-sek-150m-rights-issue-to-advance-kidney-protection-drug-development 2025-02-17T13:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-racial-and-ethnic-disparities-in-psoriatic-arthritis-care-and-research 2025-02-17T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-racial-and-ethnic-disparities-in-psoriatic-arthritis-care-and-research 2025-02-17T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dsmb-endorses-safety-of-foresee-s-camcevi-in-pediatric-precocious-puberty-trial 2025-02-17T10:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dsmb-endorses-safety-of-foresee-s-camcevi-in-pediatric-precocious-puberty-trial 2025-02-17T10:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-and-fdc-initiate-major-drug-recalls-in-us-market-over-quality-concerns 2025-02-17T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-and-fdc-initiate-major-drug-recalls-in-us-market-over-quality-concerns 2025-02-17T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-sobi-s-efanesoctocog-alfa-for-haemophilia-a-treatment 2025-02-17T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-mhra-approves-sobi-s-efanesoctocog-alfa-for-haemophilia-a-treatment 2025-02-17T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/higher-calcium-intake-associated-with-29-lower-colorectal-cancer-risk-in-large-nih-aarp-study 2025-02-17T08:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-calcium-intake-associated-with-29-lower-colorectal-cancer-risk-in-large-nih-aarp-study 2025-02-17T08:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/edx-medical-unveils-novel-multi-biomarker-test-for-enhanced-prostate-cancer-detection 2025-02-17T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edx-medical-unveils-novel-multi-biomarker-test-for-enhanced-prostate-cancer-detection 2025-02-17T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-phase-2-trial-of-tpx-115-cell-therapy-for-rotator-cuff-tears 2025-02-17T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-phase-2-trial-of-tpx-115-cell-therapy-for-rotator-cuff-tears 2025-02-17T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/lunsumio-shows-durable-3-year-remission-in-follicular-lymphoma-setting-new-benchmark-for-bispecific-antibodies 2025-02-17T07:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lunsumio-shows-durable-3-year-remission-in-follicular-lymphoma-setting-new-benchmark-for-bispecific-antibodies 2025-02-17T07:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-launches-for-novel-extracellular-vesicle-therapy-in-crohn-s-fistulas 2025-02-17T07:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-trial-launches-for-novel-extracellular-vesicle-therapy-in-crohn-s-fistulas 2025-02-17T07:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/blue-light-cystoscopy-reveals-hidden-bladder-tumors-improves-cancer-staging-in-major-registry-study 2025-02-17T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-light-cystoscopy-reveals-hidden-bladder-tumors-improves-cancer-staging-in-major-registry-study 2025-02-17T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/leading-biotech-companies-to-convene-at-6th-cytokine-based-drug-development-summit-2025-in-boston 2025-02-17T06:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leading-biotech-companies-to-convene-at-6th-cytokine-based-drug-development-summit-2025-in-boston 2025-02-17T06:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/aav-gene-therapy-market-projected-to-reach-107-2-billion-by-2035-growing-at-40-cagr 2025-02-17T06:27:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aav-gene-therapy-market-projected-to-reach-107-2-billion-by-2035-growing-at-40-cagr 2025-02-17T06:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-data-shows-promise-for-immunotherapy-combinations-in-metastatic-nsclc-treatment 2025-02-17T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-data-shows-promise-for-immunotherapy-combinations-in-metastatic-nsclc-treatment 2025-02-17T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cellistic-launches-immune-cloaked-ipsc-cell-lines-to-accelerate-cell-therapy-development 2025-02-17T05:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellistic-launches-immune-cloaked-ipsc-cell-lines-to-accelerate-cell-therapy-development 2025-02-17T05:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/texas-oncology-pioneers-solutions-for-financial-barriers-and-rural-clinical-trial-access 2025-02-17T05:42:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-oncology-pioneers-solutions-for-financial-barriers-and-rural-clinical-trial-access 2025-02-17T05:42:45+00:00 hourly 0.9 https://trial.medpath.com/news/treatment-sequencing-strategies-for-brca-mutated-early-stage-tnbc-balancing-parp-inhibition-and-immunotherapy 2025-02-17T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treatment-sequencing-strategies-for-brca-mutated-early-stage-tnbc-balancing-parp-inhibition-and-immunotherapy 2025-02-17T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-second-fast-track-designation-to-alginomics-rz-001-for-hepatocellular-carcinoma-treatment 2025-02-17T04:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-second-fast-track-designation-to-alginomics-rz-001-for-hepatocellular-carcinoma-treatment 2025-02-17T04:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/tga-approves-wegovy-for-cardiovascular-disease-prevention-in-overweight-patients 2025-02-17T04:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tga-approves-wegovy-for-cardiovascular-disease-prevention-in-overweight-patients 2025-02-17T04:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/cdk4-6-inhibitors-show-consistent-benefits-in-premenopausal-advanced-breast-cancer-patients-across-major-trials 2025-02-17T03:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdk4-6-inhibitors-show-consistent-benefits-in-premenopausal-advanced-breast-cancer-patients-across-major-trials 2025-02-17T03:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-topical-acne-therapies-show-promising-results-in-clinical-trials 2025-02-17T01:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-topical-acne-therapies-show-promising-results-in-clinical-trials 2025-02-17T01:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-second-fast-track-designation-to-innovent-s-ibi363-for-advanced-squamous-nsclc-treatment 2025-02-17T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-second-fast-track-designation-to-innovent-s-ibi363-for-advanced-squamous-nsclc-treatment 2025-02-17T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/auckland-researchers-launch-clinical-trial-to-investigate-5fu-chemotherapy-cardiotoxicity 2025-02-17T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auckland-researchers-launch-clinical-trial-to-investigate-5fu-chemotherapy-cardiotoxicity 2025-02-17T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/nx-taiwan-achieves-historic-medical-device-qms-certification-first-among-japanese-companies 2025-02-17T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nx-taiwan-achieves-historic-medical-device-qms-certification-first-among-japanese-companies 2025-02-17T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-thermo-fisher-s-multiplex-test-for-simultaneous-detection-of-covid-19-flu-and-rsv 2025-02-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-thermo-fisher-s-multiplex-test-for-simultaneous-detection-of-covid-19-flu-and-rsv 2025-02-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ps1m-grant-awarded-to-develop-novel-bama-inhibitor-against-drug-resistant-bacteria 2025-02-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ps1m-grant-awarded-to-develop-novel-bama-inhibitor-against-drug-resistant-bacteria 2025-02-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-in-renal-cell-carcinoma-show-critical-geographic-and-economic-disparities 2025-02-16T22:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trials-in-renal-cell-carcinoma-show-critical-geographic-and-economic-disparities 2025-02-16T22:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-myeloablative-hsct-protocol-shows-promise-for-kidney-transplant-immune-tolerance 2025-02-16T22:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-non-myeloablative-hsct-protocol-shows-promise-for-kidney-transplant-immune-tolerance 2025-02-16T22:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/navenibart-shows-promise-in-reducing-hereditary-angioedema-attacks-in-phase-1b-2-trial 2025-02-16T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navenibart-shows-promise-in-reducing-hereditary-angioedema-attacks-in-phase-1b-2-trial 2025-02-16T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-cancer-drug-outperforms-merck-s-keytruda-in-landmark-lung-cancer-trial 2025-02-16T22:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-cancer-drug-outperforms-merck-s-keytruda-in-landmark-lung-cancer-trial 2025-02-16T22:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/access-trial-shows-promising-survival-rates-with-ptcy-gvhd-prophylaxis-in-hla-mismatched-transplants 2025-02-16T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/access-trial-shows-promising-survival-rates-with-ptcy-gvhd-prophylaxis-in-hla-mismatched-transplants 2025-02-16T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/orca-t-immunotherapy-shows-enhanced-t-cell-activation-pattern-in-hematologic-malignancies-study 2025-02-16T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orca-t-immunotherapy-shows-enhanced-t-cell-activation-pattern-in-hematologic-malignancies-study 2025-02-16T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/lenvatinib-tislelizumab-combo-shows-promising-93-response-rate-in-rare-hereditary-kidney-cancer 2025-02-16T17:01:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenvatinib-tislelizumab-combo-shows-promising-93-response-rate-in-rare-hereditary-kidney-cancer 2025-02-16T17:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-shows-success-in-training-healthcare-providers-on-plant-based-diet-counseling 2025-02-16T16:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-shows-success-in-training-healthcare-providers-on-plant-based-diet-counseling 2025-02-16T16:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-aflibercept-shows-superior-fluid-control-in-96-week-pulsar-trial-analysis-for-wet-amd 2025-02-16T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-aflibercept-shows-superior-fluid-control-in-96-week-pulsar-trial-analysis-for-wet-amd 2025-02-16T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-samsung-bioepis-denosumab-biosimilars-for-bone-health-conditions 2025-02-16T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-samsung-bioepis-denosumab-biosimilars-for-bone-health-conditions 2025-02-16T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-leads-national-trial-of-novel-jellyfish-inspired-brain-aneurysm-device 2025-02-16T13:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wvu-leads-national-trial-of-novel-jellyfish-inspired-brain-aneurysm-device 2025-02-16T13:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tarlatamab-as-first-dll3-targeted-therapy-for-small-cell-lung-cancer 2025-02-16T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tarlatamab-as-first-dll3-targeted-therapy-for-small-cell-lung-cancer 2025-02-16T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/five-novel-9-month-oral-regimens-show-promise-in-phase-3-trial-for-drug-resistant-tb 2025-02-16T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-novel-9-month-oral-regimens-show-promise-in-phase-3-trial-for-drug-resistant-tb 2025-02-16T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/reverse-switch-from-infliximab-biosimilar-to-remicade-shows-sustained-efficacy-in-ibd-patients 2025-02-16T04:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reverse-switch-from-infliximab-biosimilar-to-remicade-shows-sustained-efficacy-in-ibd-patients 2025-02-16T04:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/novel-oral-psoriasis-therapies-show-promise-tyk2-inhibitors-lead-breakthrough-advances 2025-02-16T04:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-oral-psoriasis-therapies-show-promise-tyk2-inhibitors-lead-breakthrough-advances 2025-02-16T04:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulator-scrutinizes-moderna-over-covid-19-vaccine-trial-recruitment-practices 2025-02-16T02:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-regulator-scrutinizes-moderna-over-covid-19-vaccine-trial-recruitment-practices 2025-02-16T02:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dual-receptor-car-t-cell-therapy-a2b694-enters-clinical-trial-for-pancreatic-cancer-treatment 2025-02-16T01:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-dual-receptor-car-t-cell-therapy-a2b694-enters-clinical-trial-for-pancreatic-cancer-treatment 2025-02-16T01:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/cemiplimab-plus-chemotherapy-shows-promise-in-advanced-penile-cancer-epic-trial 2025-02-16T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cemiplimab-plus-chemotherapy-shows-promise-in-advanced-penile-cancer-epic-trial 2025-02-16T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/avelumab-maintenance-shows-consistent-survival-benefits-in-advanced-urothelial-cancer-patients-with-and-without-diabetes 2025-02-16T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avelumab-maintenance-shows-consistent-survival-benefits-in-advanced-urothelial-cancer-patients-with-and-without-diabetes 2025-02-16T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/fotivda-opdivo-combination-shows-comparable-quality-of-life-outcomes-to-fotivda-alone-in-advanced-kidney-cancer 2025-02-16T00:01:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fotivda-opdivo-combination-shows-comparable-quality-of-life-outcomes-to-fotivda-alone-in-advanced-kidney-cancer 2025-02-16T00:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-seeks-japanese-approval-for-novel-fgfr-inhibitor-tasurgratinib-in-biliary-tract-cancer 2025-02-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-seeks-japanese-approval-for-novel-fgfr-inhibitor-tasurgratinib-in-biliary-tract-cancer 2025-02-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/calypso-trial-savolitinib-durvalumab-combo-shows-promising-results-in-met-driven-papillary-renal-cancer 2025-02-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calypso-trial-savolitinib-durvalumab-combo-shows-promising-results-in-met-driven-papillary-renal-cancer 2025-02-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-casgevy-for-beta-thalassemia-marking-second-indication-for-first-crispr-based-therapy 2025-02-15T23:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-casgevy-for-beta-thalassemia-marking-second-indication-for-first-crispr-based-therapy 2025-02-15T23:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/cabozantinib-shows-promising-results-for-renal-cell-carcinoma-patients-with-brain-metastases-in-phase-2-trial 2025-02-15T22:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabozantinib-shows-promising-results-for-renal-cell-carcinoma-patients-with-brain-metastases-in-phase-2-trial 2025-02-15T22:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-s-oral-ms-drug-fty720-shows-promising-two-year-efficacy-data-potential-2010-launch 2025-02-15T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-s-oral-ms-drug-fty720-shows-promising-two-year-efficacy-data-potential-2010-launch 2025-02-15T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-fotivda-dose-shows-superior-efficacy-in-renal-cell-carcinoma-treatment 2025-02-15T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-fotivda-dose-shows-superior-efficacy-in-renal-cell-carcinoma-treatment 2025-02-15T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/ascension-alexian-brothers-hospital-launches-novel-alzheimer-s-treatment-trials-including-at-home-injectable-option 2025-02-15T22:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascension-alexian-brothers-hospital-launches-novel-alzheimer-s-treatment-trials-including-at-home-injectable-option 2025-02-15T22:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/clear-trial-update-lenvatinib-pembrolizumab-combination-shows-sustained-efficacy-in-advanced-renal-cell-carcinoma 2025-02-15T19:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clear-trial-update-lenvatinib-pembrolizumab-combination-shows-sustained-efficacy-in-advanced-renal-cell-carcinoma 2025-02-15T19:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/uva-launches-30m-trial-to-test-ketamine-for-life-threatening-seizures 2025-02-15T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-launches-30m-trial-to-test-ketamine-for-life-threatening-seizures 2025-02-15T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/duke-scientists-develop-revolutionary-hydrogel-implant-surpassing-natural-knee-cartilage-strength 2025-02-15T16:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-scientists-develop-revolutionary-hydrogel-implant-surpassing-natural-knee-cartilage-strength 2025-02-15T16:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/mediprint-s-weekly-glaucoma-contact-lens-shows-promise-in-phase-2b-trial-patents-secured-through-2043 2025-02-15T16:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediprint-s-weekly-glaucoma-contact-lens-shows-promise-in-phase-2b-trial-patents-secured-through-2043 2025-02-15T16:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/evolution-of-crs-and-icans-management-in-car-t-cell-therapy-new-consensus-guidelines-transform-treatment-approach 2025-02-15T15:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolution-of-crs-and-icans-management-in-car-t-cell-therapy-new-consensus-guidelines-transform-treatment-approach 2025-02-15T15:39:49+00:00 hourly 0.9